Complete reference list

Complete Reference List (403 Sources)

All sources are peer-reviewed systematic reviews, meta-analyses, randomized controlled trials, or major clinical studies from 2016-2026. Emphasis on 2024-2026 publications.

Understanding OLT [1-9]

• [1] Advancements in Treatment of OLT - J Orthop Surg Res (2024)
• [2] OLT Review: Osteochondritis Dissecans - Cartilage (2021)
• [3] Treatment of OLT: Systematic Review - Knee Surg Sports Traumatol Arthrosc (2009)
• [4] Current Treatment Concepts for OLT (2021)
• [5] PRP for OLT: Systematic Review of Clinical Trials (2020)
• [6] Critical Defect Size for Poor Outcome - Am J Sports Med (2009)
• [7] Predictors of Microfracture Outcomes (2022)
• [8] Long-term Prognosis After Nonoperative Treatment: 14-Year Follow-up (2020)
• [9] Natural History of Nonoperatively Treated OLT (2014)

Conservative Management [10-14]

• [10] Non-operative Management: Systematic Review - KSSTA (2023)
• [11] Non-operative Management: Treatment Modalities Review (2023)
• [12] Treatment Principles for OLT in Foot and Ankle (2013)
• [13] Nonoperative Treatment Outcomes - Foot Ankle Int (2025)
• [14] OLT in Skeletally Immature Patients (2022)

Hyaluronic Acid / PRP [15-19]

• [15] HA as Adjunct to Microfracture: Systematic Review of RCTs (2022)
• [16] Ankle Injections for OLT and OA: Meta-analysis (2020)
• [17] HA as Treatment for Ankle OA (2009)
• [18] PRP and HA After Microfracture - Foot Ankle Int (2015)
• [19] PRP Augmentation in Microfracture: Meta-Analysis (2023)

Bone Marrow Stimulation / Microfracture [20-28]

• [20] Midterm Outcomes of BMS: Systematic Review (2020)
• [21] Failed Primary OLT Treatment: BMS Outcomes Review (2022)
• [22] 10-Year Survival Rate of Arthroscopic BMS - JBJS (2024)
• [23] Systematic Review of BMS: Level and Quality of Studies (2017)
• [24] DGOU 2024 Recommendations for OLT Management
• [25] AMIC Chondro-Gide Overview - Geistlich
• [26] OLT with Small Cysts: Microfracture Meta-Analysis (2025)
• [27] Autologous Osteochondral Transfer vs BMS for Large Cystic OLT (2021)
• [28] Review of Arthroscopic BMS Techniques of Talus (2015)

BioCartilage / Scaffolds / AMIC [29-34]

• [29] Extracellular Matrix Cartilage Allograft: Systematic Review (2024)
• [30] BioCartilage vs Microfracture Outcomes - Arthrex
• [31] AMIC Efficacy Mid-Long Term: Meta-Analysis (2024)
• [32] AMIC Chondro-Gide in Talus - Geistlich
• [33] Typical Complications After AMIC for Ankle (2023)
• [34] AMIC with Biomimetic Scaffold: Clinical and MRI Outcomes (2017)

OATS / Autograft [35-40]

• [35] Long-term Outcomes After OAT: 10.2 Year Follow-up (2016)
• [36] OAT of Talus: Long-term Results with Novel Technique (2020)
• [37] Osteochondral Transplantation: Long-term Clinical and MRI (2011)
• [38] Allograft vs Autograft for Talus: Meta-analysis (2022)
• [39] Knee Donor-site Morbidity After Mosaicplasty: Systematic Review (2016)
• [40] Predictors of Donor Site Morbidity (2025)

Osteochondral Allograft [41-45]

• [41] Fresh Osteochondral Allograft for OLT: Systematic Review (2021)
• [42] Osteochondral Allograft Transfer for OLT: Systematic Review (2016)
• [43] Osteochondral Allograft of the Talus (2014)
• [44] Revision Options for Failed Bulk Talar Allograft: Systematic Review (2020)
• [45] Editorial: Bulk Osteochondral Talar Grafts and Future Surgery (2017)

Juvenile Cartilage / DeNovo [46-47]

• [46] Particulated Juvenile Cartilage Allograft: Systematic Review (2024)
• [47] Long-term Results of Particulated Juvenile Allograft: 11-Year Case (2023)

Subchondralplasty [48-53]

• [48] Arthroscopic Management of Large Subchondral Talar Cyst (2023)
• [49] Subchondralplasty: Novel Treatment Strategy (2023)
• [50] Arthroscopic Calcium Phosphate Injection for OLT (2024)
• [51] Complications Following Subchondroplasty (2024)
• [52] Retrograde Drilling with 3D Navigation (2023)
• [53] Retrograde Drilling for OLT with Subchondral Cyst: Case Report (2016)

Fusion vs. Replacement [54-62]

• [54] Total Ankle Arthroplasty vs Fusion (2024)
• [55] Modern TAA vs Arthrodesis: Meta-Analysis (2020)
• [56] Total Ankle Replacement in Young Patients (2021)
• [57] TAA Survivorship in Patients <55 Years (2022)
• [58] Burden of Revision TAA Has Increased (2023)
• [59] TAA in Patients Under 50: Should Indications Be Revised? (2013)
• [60] Ankle Arthrodesis: Long-term Review of Literature (2019)
• [61] Clinical and Radiological Mid-Long Term Outcomes After Fusion (2019)
• [62] Outcomes of Conversion of Ankle Fusion to TAA (2024)

Additional 2024-2025 Sources [63-74]

• [63] OCD/Osteochondral Defect Overview - Mass General
• [64] Return to Sports After OLT Treatment: Systematic Review (2019)
• [65] Juvenile OLT: Systematic Review (2023)
• [66] Pediatric OLT: Conservative Treatment Outcomes (2020)
• [67] PRP for Ankle Cartilage Injuries: Meta-Analysis (2024)
• [68] PRP Complications: Systematic Review (2025)
• [69] Adjunctive Therapies for Microfracture: Network Meta-Analysis (2024)
• [70] HA for Ankle: CADTH Rapid Review (2024)
• [71] BMS Mid-to-Long Term: Systematic Review (2025)
• [72] BMS 5-Year Follow-Up (2025)
• [73] AMIC 10-Year Cohort Study (2025)
• [74] Arthroscopic AMIC 5-Year Follow-Up (2024)

OATS/Autograft Extended [75-78]

• [75] OATS Systematic Review Update (2024)
• [76] Novel Arthroscopic OATS Technique (2024)
• [77] Single-Plug OATS Technique (2024)
• [78] Ipsilateral Talus as Donor Site (2024)

Allograft Extended [79-82]

• [79] Fresh OCA Outcomes Review (2024)
• [80] Fresh Talar Allograft Outcomes (2025)
• [81] Bulk vs Shell Allograft Comparison (2024)
• [82] Revision Allograft Outcomes (2024)

DeNovo/Subchondralplasty Extended [83-85]

• [83] Particulated Juvenile Cartilage 5-Year (2024)
• [84] DeNovo NT Product Information - Zimmer Biomet
• [85] Subchondralplasty Systematic Review (2024)

Fusion/TAA Extended [86-89]

• [86] TAA vs Arthrodesis - JBJS (2024)
• [87] 3D-Printed Custom TAA Implants (2024)
• [88] National Registry TAA Data (2025)
• [89] Arthrodesis Techniques Update (2024)

ACI/MACI [90-91]

• [90] ACI 20-Year Follow-Up (2024)
• [91] MACI Systematic Review (2024)

Stem Cell / Regenerative [92-94]

• [92] DGOU 2024: MSC in OLT Treatment
• [93] MSC with Hydrogel Scaffold Case Study (2025)
• [94] MSC-Derived Exosomes for Knee OA (2024)

Shockwave Therapy (ESWT) [95-98]

• [95] ESWT + Microfracture + HA for OLT (2025)
• [96] ESWT Mechanism for Cartilage Repair (2024)
• [97] MF+ESWT vs MF+PRP: Comparative Study (2023)
• [98] Combined ESWT + BMC Transplantation (2017)

PEMF Therapy [99-102]

• [99] PEMF for Bone and Cartilage: Review (2025)
• [100] PEMF for Knee OA: In Vitro Study (2024)
• [101] PEMF and Sirt1/NF-κB Pathway (2025)
• [102] NASA PEMF Technology Development

Physical Therapy & Rehabilitation [103-106]

• [103] Variation in Rehab Protocols: 200+ Studies (2024)
• [104] OLT Management - Physiopedia
• [105] OATS Rehabilitation Protocol - Mass General
• [106] Recent Advances in OLT Treatment: Narrative Review (2025)

Lifestyle & BMI [107]

• [107] BMI Influence on OLT Outcomes: German Registry (2025)

Nutritional Supplements [108-111]

• [108] Glucosamine/Chondroitin Systematic Review (2025)
• [109] Cartilage-Supporting Supplements RCT (2025)
• [110] NIH/NCCIH: Glucosamine and Chondroitin
• [111] Collagen Derivatives Meta-Analysis (2024)

Gene Therapy [112-114]

• [112] Gene Therapy for OA: Precision Medicine (2025)
• [113] Clinical Trials on Biologics for Cartilage (2022)
• [114] Next-Generation Cartilage Repair (2024)

Return to Sport [115-119]

• [115] Return to Sports After OLT: 2,347 Cases (2019)
• [116] OLT in Athletes: Up-to-Date Review (2017)
• [117] Return to Sports After BMDCT (2016)
• [118] Sports After OCA Transplantation (2024)
• [119] Pediatric Microfracture Return to Sport (2024)

Imaging & Staging [120-123]

• [120] Evaluation and Management of OLT (2016)
• [121] Staging of OLT: MRI and Cone Beam CT (2018)
• [122] Quantitative T2 Mapping in Ankle Trauma (2025)
• [123] MRI-Based Talar Cartilage Thickness Accuracy (2022)

Risk Factors [124-127]

• [124] Smoking and AOT Outcomes: 5-Year Study (2025)
• [125] Medial OLT in CLAI vs Ankle Varus (2025)
• [126] Concomitant OLT in Ankle Instability (2024)
• [127] CLAI Effects on OLT Outcomes (2024)

Surgical Approaches [128-131]

• [128] DGOU 2024 OLT Recommendations
• [129] MMO in German Cartilage Registry (2024)
• [130] MMO vs AMO Comparison (2025)
• [131] Medial Talar Dome Lesions Outcomes (2024)

Metal Resurfacing [132-133]

• [132] Metal Resurfacing After Failed Surgery (2018)
• [133] OLT: Are We Ready for Metal? (2018)

Revision Surgery [134-135]

• [134] Realignment for Failed OAT (2024)
• [135] Repeat Arthroscopy and Microfracture (2024)

Cryopreserved Allografts [136-138]

• [136] Cryopreserved vs Fresh OCA: Biomechanics (2025)
• [137] Osteochondral Allograft - StatPearls
• [138] Cryopreserved Thin Laser-Etched Allograft (2020)

3D Bioprinting & Future [139-140]

• [139] 3D Bioprinted Scaffolds for Osteochondral Regeneration (2025)
• [140] 3D-Printed Biphasic Scaffolds (2025)

Psychological Factors [141-142]

• [141] Depression and Anxiety in OLT Patients (2024)
• [142] Preoperative Anxiety in Orthopaedic Surgery (2025)

Platelet-Rich Fibrin [143-144]

• [143] PRF for High-Grade OLT (2024)
• [144] PRP with AOT for OLT + CLAI (2025)

Osteoperiosteal Revision / TOPIC / AOPT [145-147]

• [145] TOPIC 5-Year Prospective Outcomes (2024)
• [146] AOPT vs AOCT Comparison: 65 vs 65 Patients (2025)
• [147] Return to Sport After TOPIC (2026)

Revision Surgery Extended [148-149]

• [148] Non-Primary OLT Systematic Review: 50 Studies, 806 Ankles (2024)
• [149] Non-Primary BMS Prospective Study (2026)

Postoperative Cysts [150]

• [150] Postoperative Cysts After Cartilage Repair: Meta-Analysis (2025)

OATS/Autograft Extended [151-152]

• [151] 10-Year AOT Outcomes Review (2024)
• [152] Multi-Plug AOT for Large Lesions (2026)

Allograft Extended [153]

• [153] Fresh OCA 9.2-Year Follow-Up: Return to Sport (2024)

BioCartilage / AMIC Extended [154]

• [154] AMIC/Scaffold Long-Term Data (2024)

Metal Resurfacing Extended [155-156]

• [155] Episealer Talus: Patient-Specific Resurfacing Technique (2025)
• [156] Episealer Talus Multicenter Early Outcomes (2025)

Alignment & Instability Extended [157]

• [157] Alignment, Instability, and OLT Surgical Planning (2025)

Total Talar Replacement [158-215]

• [158] Technique for Talectomy and Total Talus Replacement — Foot Ankle Clin (2024)
• [159] Total Talus Replacements: Systematic Review — Jennison et al. (2023)
• [160] restor3d Total Talus Replacement — FDA HDE Approval (2023)
• [161] 4WEB Medical Talar Replacement Device — FDA HDE Approval (2024)
• [162] Outcomes Following Total Talus Replacement: Systematic Review — Johnson et al. (2022)
• [163] Total Talus Replacement Using 3D-Printed Pure Titanium Prosthesis (2025)
• [164] Outcomes of Cobalt-Chrome 3D-Printed TTR — Mitra et al. (2025)
• [165] Long-Term Clinical Results of Total Talar Replacement at 10+ Years — Morita et al. (2022)
• [166] Initial Safety of Total Talus Replacement for AVN — Abar et al. (2024)
• [167] Revision Total Talus Replacement with Constrained Implant: 3 Cases (2024)
• [168] Lessons from Revision Total Ankle Replacement: Tibias Fail Early, Taluses Fail Late (2024)
• [213] Partial Ankle Arthroplasty: Talus Resurfacing and Talar Hemiarthroplasty Prospective Series — JAPMA (May–Jun 2024)
• [214] Partial Talus Replacement (PTR) for Severe OLT — Custom 3D-Printed Hemiarthroplasty Case Report (2023)
• [215] Short-term Results of Talar Hemiarthroplasty (Ankle Spacer) for Talar-Sided Cartilage Loss — Shimozono et al. (2023)

2026 Updates [169-180]

• [169] Second-Look Arthroscopy: BMS Inferior to Other Techniques — Vreeken et al., CARTILAGE (2026)
• [170] Immediate vs Delayed Weightbearing After Arthroscopic BMS — Foot Ankle Int (2025)
• [171] Nonoperative Treatment: Long-Term Survival at 5+ Years — Buck et al., CARTILAGE (2026)
• [172] TAR vs Ankle Fusion: 25-Year, 41,000-Patient Registry — Hennessy et al., Foot Ankle Int (2026)
• [173] 15-PGDH Inhibition Promotes Cartilage Regeneration — Science (2026)
• [174] MASCOT: MACI vs BMS for Talar OLT — Vericel Phase 3 RCT (2025-2026)
• [175] Hy2Care CartRevive Hydrogel — FDA IDE Approval for US Trial (2026)
• [176] Costal Cartilage Transplantation for Hepple V OLT — Eur J Med Res (2025)
• [177] Cartilage Injuries of the Ankle: New Beginnings — Kerkhoffs et al., CARTILAGE Special Issue (2026)
• [178] OLT Classification: No Consensus (262 Studies, 11,785 Patients) — Van Diepen et al., CARTILAGE (2026)
• [179] Traumatic Impact Immediately Changes Talar Cartilage Properties — Blom et al., CARTILAGE (2026)
• [180] Pain in OLT: Limited Correlation with CT Findings — Hollander et al., Foot Ankle Int (2026)

HA Injection Optimization [181-189]

• [181] Mei-Dan et al. — HA for Osteochondritis Dissecans of Ankle (Foot Ankle Int 2008)
• [182] Hwang et al. — HA Injections After Failed Microfracture (Foot Ankle Int 2020)
• [183] Navarro-Sarabia — AMELIA Project 40-month HA Repeat Dosing (Ann Rheum Dis 2011)
• [184] Altman 2018 — Real-World Repeated HA Courses Delaying TKA
• [185] Witteveen Cochrane Review 2015 — HA for Ankle OA
• [186] Han, Park, Kim 2014 — Prognostic Factors for HA in Ankle OA (Yonsei Med J)
• [187] Boffa, Filardo et al. 2021 — Ankle Injections Systematic Review (Int Orthop)
• [188] Mei-Dan et al. 2012 — PRP vs HA for Talar OLT (Am J Sports Med)
• [189] Buda et al. 2023 — HA Scaffold + BMAC 10-year Results for OLT

Revision Allograft [190-196]

• [190] Gaul/Bugbee — Long-term Follow-up of Revision OCA of the Ankle (Foot Ankle Int 2018)
• [191] Williams et al. — Histopathology of Failed Fresh Talar OCA
• [192] Juels CA, So E, Seidenstricker C, Holmes J, Scott RT — A Comparison of Outcomes of Revision Surgical Options for the Treatment of Failed Bulk Talar Allograft Transfer: A Systematic Review, J Foot Ankle Surg 2020, PMID 32972848. 11 studies, 522 ankles. Author corrected 2026-08-06 — this entry credited “Shah” for months; no such author is on the paper and no Shah review of this topic exists. Duplicates [44]
• [193] Van Dijk Editorial — Bulk Talar Grafts Compromise Future Salvage
• [194] Wang/Bugbee 2025 — Multivariable Analysis of 560 Knees OCA (AJSM)
• [195] Gaul 2019 — Salvage Arthrodesis/TAR After Failed OCA (Foot Ankle Int)
• [196] Ahmad — Systematic Review of OCA Immunology

Activity-Specific Evidence [197-204]

• [197] Anderson et al. — Talar Contact Pressure during Stance (DEM/FEA)
• [198] Pellikaan et al. — Lower Limb Joint Loading During High-Impact Activities (JBMR Plus 2024)
• [199] Squat Joint Contact Forces in Powerlifters (PLoS One 2025)
• [200] Ruan et al. — Biomechanical Influence of Defected Cartilage on OLT Progression: 3D FEA (Orthop Surg 2023)
• [201] Fiske/Bugbee 2024 — Sports Participation After OCA of Talus (AJSM)
• [202] Mechanotransduction Pathways in Articular Chondrocytes (Bone Research 2023)
• [203] Sports Activity with Ankle OA and Total Ankle Arthroplasty (JCM 2024)
• [204] Kulmala et al. — Highly Cushioned Shoes Increase Leg Stiffness (Sci Rep 2018)

Bracing & Orthotics [205-209]

• [205] van Diepen — Non-operative Management of OLT Systematic Review
• [206] Song et al. — Lace-up Brace Tibiotalar Kinematics (Front Bioeng Biotechnol 2023)
• [207] Semi-Rigid Brace 3D Stress-MRI Cartilage Contact Study
• [208] Corr et al. — Arizona Brace Prospective Cohort (Foot Ankle Orthop 2022)
• [209] Raymond et al. — Bracing & Proprioception Meta-Analysis

Clinical Trials [210-212]

• [210] MASCOT (NCT06915233) — MACI Phase 3 RCT for Talar OLT (Vericel)
• [211] Paragon 28 Patient Specific Talus Spacer PAS (NCT05364606)
• [212] Restor3d PROCLAIM Total Talus Replacement (NCT06311331)

July 2026 Research Log [216-228]

Added by the weekly literature sweep of July 20–26, 2026. Publication dates verified against PubMed, Europe PMC, Crossref, or ClinicalTrials.gov records.

• [216] Bridging Conservative Management With Injectable Orthobiologic Therapies: Proceedings of the International Consensus Meetings on Cartilage Repair of the Ankle — Tham, Rubin, Butler et al., Foot Ankle Spec (epub 2026-07-24)
• [217] Patient-Specific Talar Resurfacing Improves Pain and Function at 24 Months in OLT — Mosca, Caravelli et al., Knee Surg Sports Traumatol Arthrosc (epub 2026-07-13)
• [218] Bone Tracer Uptake in SPECT/CT as an Indicator for Treatment Decision-Making in Cystic OLT — Bone Joint Res (2026-07-06)
• [219] Arthroscopic Autologous Cancellous Bone Grafting + PRP vs Autologous Osteochondral Transplantation for Large Medial Cystic OLT — Han et al., Research Square preprint, not peer reviewed (posted 2026-07-17)
• [220] Ten-Year Follow-up After Arthroscopic AMIC Repair of OLT (NCT07725770) — IRCCS Ospedale Galeazzi-Sant'Ambrogio (first posted 2026-07-24)
• [221] Letter Regarding: Radiologic Progression of Talar OLT with Subchondral Cyst — Dahmen, Hollander, Kerkhoffs, Foot Ankle Int (2026-07-22)
• [222] Response to Letter Regarding: Radiologic Progression of Talar OLT with Subchondral Cyst — Seo, Choi, Lee, Foot Ankle Int (2026-07-22)
• [223] Combined Allogeneic Osteochondral Mosaicplasty and Osteotomy for Hepple V OLT: Efficacy, Inflammatory Response and Prognostic Factors — Ann Med (2026-07-01)
• [224] Platelet-Rich Plasma in the Management of Foot and Ankle Pathologies — Foot Ankle Spec (epub 2026-07-15)
• [225] Clinical Outcomes and Pin Insertion Angles After Osteochondral Fragment Fixation for Medial OLT With and Without Medial Malleolus Osteotomy — J ISAKOS (epub 2026-07-15)
• [226] Identifying Potential Optimal Donor Graft for Talar Osteochondral Transplantation: Finite Element Analysis of Femoral Condyle Sites — Med Eng Phys (2026-07-21)
• [227] Total Ankle Arthroplasty and Ankle Arthrodesis Complications and Costs Based on Surgeon Specialty — JB JS Open Access (2026-07-17)
• [228] AAOS Clinical Practice Guideline: Management of Ankle Osteoarthritis — moderate recommendation against routine PRP; strong recommendation against HA alone; no reliable evidence for stem cell therapy (2026)

July 27, 2026 Research Log [229-237]

Added by the weekly literature sweep of July 27, 2026, covering items dated July 18–27 that were not captured in the previous sweep. Publication and posting dates verified against Europe PMC, Crossref, ClinicalTrials.gov, openFDA, or the publisher's own record — not from search-result snippets. Two entries are older publications that had not previously been recorded; their true dates are given rather than the date they surfaced.

• [229] Cell-Based Therapies for Post-Traumatic Ankle Osteoarthritis and Osteochondral Lesions of the Talus: A Systematic Scoping Review of an Emerging and Heterogeneous Evidence Base — Jeon, Kim, Lee, Bioengineering 13(7):843 (2026-07-22)
• [230] ACTiVION-II: Phase 3 Trial of TissueGene-C in Knee Osteoarthritis (NCT03291470) — Kolon TissueGene; topline reported 2026-07-20, both co-primary endpoints missed
• [231] Comments on: “Medial vs. Anterior Malleolar Osteotomy in Osteochondral Autologous Transplantation for Hepple V Talar Lesions” — Chen Y., Orthop Traumatol Surg Res (2026-07-21). Paywalled, no abstract; substance unverified
• [232] Medial vs. Anterior Malleolar Osteotomy in Osteochondral Autologous Transplantation for Hepple V Talar Lesions: A Retrospective Study — Bai, Liu, Yan et al., Orthop Traumatol Surg Res (2025-07-10) — the paper being commented on
• [233] Regentis Biomaterials Receives Japanese Patent Allowance for GelrinC Manufacturing Process (2026-07-20) — intellectual property, no new clinical data
• [234] Spatial Transcriptomics of hiPSC-Derived MSC Repair in Human OA Cartilage and Murine DMM Model — bioRxiv preprint, not peer reviewed (posted 2026-07-23)
• [235] 2D-3D Registration for Gait Analysis of Distal Tibiofibular and Tibiotalar Joint Motion — Research Square preprint, not peer reviewed (posted 2026-07-27); 16 healthy adults, normative kinematics
• [236] Efficacy of Ultra-high and High Molecular Weight Cross-Linked Hyaluronic Acids Compared with Saline in Knee Osteoarthritis: A Randomized Controlled Trial — Kanitnate, Charnwichai, Tanariyakul, Tammachote, JBJS Open Access 11(2) (published 2026-04, epub 2026-05-12; surfaced by trade coverage 2026-07-20). Level I, n=276, knee
• [237] Episurf Medical Initiates Dual-Track Process for its Medtech Operations (2026-04-20) — company press release; medtech to move outside the group by end of 2026. Episealer Talus is CE-marked but has no FDA clearance (Episurf's only US 510(k) is K221048, patellofemoral knee)

July 28, 2026 Research Log [238-246]

Added by the weekly literature sweep of July 28, 2026, covering items dated July 21–28 that were not captured in the two previous sweeps. Publication dates verified against Europe PMC, Crossref, ClinicalTrials.gov, or the publisher's own deposited record — not from search-result snippets. References [244]–[246] are older sources added this week: the two ankle HA trials correct a false claim previously made on this page, and the FDA safety communication had never been recorded.

• [238] Postoperative Sensory Nerve Complications Following Ankle Arthroscopy: Incidence, Risk Factors, and Clinical Course in 545 Consecutive Procedures — Roche, Lopes, Foot Ankle Int (2026-07-25). Level IV retrospective cohort; 8.4% incidence, 44.4% fully resolved at mean 13 months
• [239] Three-Dimensional Subtalar Joint Space Mapping Identifies Sinus Tarsi-Predominant Structural Compromise in Early- Versus End-Stage Varus Ankle Osteoarthritis — Mei et al., J Orthop Surg Res (2026-07-24). Simulated weight-bearing CT
• [240] Multi-Joint Gait Adaptation Patterns in Medial Ankle Osteoarthritis With and Without Concurrent Knee Osteoarthritis — Kim et al., Gait Posture 130 (2026-07-21). 42 patients (Takakura 2-3A) vs 44 controls
• [241] Peptide Therapeutics in Orthopaedics: Current Evidence and Future Directions — JBJS Am (2026-07-21). Instructional review; states no peptide-based DMOAD has achieved clinical validation
• [242] Mid-Term Clinical and Radiologic Outcomes of Augmented Microfracture With Decellularized Particulated Costal Allocartilage for Knee Cartilage Defects: Four-Year Prospective Case Series — Chung et al., Sci Rep (2026-07-22). n=40, single-arm, knee
• [243] Early Histological Advantage of CD271-Positive Adipose-Derived Mesenchymal Stromal Cells Isolated From the Infrapatellar Fat Pad in Experimental Knee Osteoarthritis — BMC Musculoskelet Disord (2026-07-21). Preclinical, athymic rat, 14 days
• [244] Safety and Efficacy of Intra-Articular Sodium Hyaluronate (Hyalgan) in a Randomized, Double-Blind Study for Osteoarthritis of the Ankle — Cohen, Altman, Hollstrom, Hollstrom, Sun, Gipson, Foot Ankle Int (2008). n=30, five weekly injections vs saline; positive, AOS p=0.041 at 3 months. Added 2026-07-28 to correct a false claim previously on this page
• [245] Intra-Articular Injection of Hyaluronic Acid Is Not Superior to Saline Solution Injection for Ankle Arthritis: A Randomized, Double-Blind, Placebo-Controlled Study — DeGroot, Uzunishvili, Weir, Al-Omari, Gomes, J Bone Joint Surg Am (2012). n=64, single injection vs saline; negative, no significant between-group difference in AOFAS at 6 or 12 weeks
• [246] UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure — FDA Safety Communication, issued 2026-06-03 (outside the sweep window; never previously recorded). AOANJRR 15-year revision 25.7% vs 15.2%, HR 1.93 (1.55–2.40); manufacturer post-approval study 31.8% revised at 10 years with 55.7% loss to follow-up; UK NJR 9.5% at 10 years. Not a recall

July 29, 2026 Research Log [247-271]

Added by the sweep of July 29, 2026, covering items dated July 26–29 not captured in the three previous sweeps. Dates verified against Crossref created, ClinicalTrials.gov API fields, Europe PMC, SEC filing dates, or a registry's own record — never from a search-result snippet. References [251]–[259] and [262]–[264] are older sources added this week because they had never been recorded: [251] and [252] materially affect the long-term decision, [253] names a treatment option not previously on this page, and [262]–[264] come from the AAOS guideline's own evidence base, which was read in full for the first time this week — correcting what this page previously said about the hyaluronic acid literature.

• [247] Surgical Intervention for Moderate-To-Large lesions (1–2.9 cm²): Proceedings of the International Consensus Meetings on Cartilage Repair of the Ankle — Rubin, Tham, Butler, Gauthier, Kennedy, Adams et al. (106 authors), Foot & Ankle Specialist (published online 2026-07-29, Crossref created 2026-07-29T10:22:06Z). Level V expert consensus, modified Delphi across the ICCRA 2017 and 2025 meetings. Supports autologous osteochondral transplantation as a primary option for cystic, uncontained and revision lesions; scaffolds viable but not superior to AOT for larger lesions. Full text not retrievable (publisher 403) — individual statement percentages unread
• [248] An International Expert Consensus Statement Defining the Best Practices and Areas of Uncertainty Concerning the Use of Orthobiologics — Kunze, Morgan, Gerhold, Nishioka, Piuzzi, Chahla, J Bone Joint Surg Am (2026-07-28), DOI 10.2106/JBJS.26.00723. Three-round Delphi, 24-member international panel, 62 final statements. Consensus reached for PRP in knee, hip and glenohumeral OA — the ankle is not among the joints reaching consensus
• [249] Sex Differences in Morphology of Osteochondral Lesions of the Talus — Gianakos, Pijnacker, Sierevelt, Geurts, Dahmen, Hemke, Stufkens, Kerkhoffs, Foot Ankle Surg (2026-07-26), DOI 10.1016/j.fas.2026.07.012. Level III cross-sectional CT, n=250 primary OLTs. Male–female size differences lost significance after adjustment for patient height; female crater-type morphology OR 2.5 (1.1–5.9)
• [250] Minimal Clinically Important Difference for FAAM-ADL After Total Ankle Arthroplasty — Thomas, Green, Sommi, West, Simonson, Hsu, Pedowitz, Parekh, Foot Ankle Int (2026-07-28), DOI 10.1177/10711007261454966. Level III retrospective cohort, n=164. MCID 12.5 (distribution) to 26.0–32.3 (anchor-based); only independent predictor of achieving MCID was lower pre-operative FAAM-ADL, OR 0.93, p<0.001
• [251] Ten Year Follow-up of a Randomized Trial of Autologous Chondrocyte Implantation Versus Alternative Forms of Surgical Cartilage Management in the Knee (ACTIVE) — Snow, Middleton, Mehta, Roberts, Grey, Richardson, Kuiper et al., Osteoarthritis and Cartilage (published online 2026-03-13, August 2026 issue), PMID 41833791, ISRCTN 48911177. Level I RCT, n=390, all of whom had failed one previous cartilage procedure. Lysholm mean difference +7.3 points favouring ACI (95% CI 2.5–12.1); sensitivity analysis for reoperations +3.8 (95% CI −1.8 to 9.5); 10-year treatment failure comparable, 29% vs 25%, HR 1.04 (0.69–1.6). Knee. Added 2026-07-29; surfaced via an in-window commentary
• [252] Indications, Causes, and Patient Risk Factors for Revision After Total Ankle Arthroplasty: A Descriptive Cross-Registry Analysis of the NJR, AOANJRR, and SwedAnkle Registries — Clinics and Practice (published 2026-07-17), PMID 42505693. 18,552 primary total ankle replacements. 10-year cumulative revision 9.54% (NJR), 13.5% (AOANJRR OA sub-cohort), ~26% (SwedAnkle); aseptic loosening leading cause in all three; age <55 vs ≥75 HR 2.00 (1.30–3.07), pre-2015 era HR 1.91, BMI ≥30 HR 1.52. Added 2026-07-29
• [253] Clinical and Radiographic Outcomes of Fibula-Preserving Supramalleolar Osteotomy Combined with Arthroscopic Modified Bröstrom Operation in Varus Ankle Osteoarthritis — Medicina (published 2026-06-23), PMID 42512764. Level IV case series, n=22, mean follow-up 17.2 months. Talar tilt 9.85°→6.09° and medial distal tibial angle 85.03°→91.26° (both p<0.001); cartilage grade stable or improved in every patient at second-look arthroscopy. Added 2026-07-29 — names a mechanical option not previously on this page
• [254] Preoperative Tibiotalar Aspiration and Biopsy Before Ankle Arthrodesis or Arthroplasty — Rougereau, Yvinou, Marmouset, Cale, Gaudot, Bauer, Stiglitz, J Foot Ankle Surg (2026-07-29), DOI 10.1053/j.jfas.2026.07.015. Level IV case series, n=27. Only 1 of 27 (4%) yielded a clinically actionable positive, in a patient with pre-existing clinical inflammation; no postoperative infectious complications
• [255] Selective Serotonin Reuptake Inhibitor Use is Associated with Increased Risk of Non-Union Following Foot and Ankle Arthrodesis: A Propensity-Matched Analysis — Stump, Mathew, Gokcen, J Foot Ankle Surg (2026-07-27), DOI 10.1053/j.jfas.2026.07.017. Level III, TriNetX, 2,216 matched pairs. Non-union HR 1.239 (6 mo) to 1.271 (3 yr); signal held for tibiotalar arthrodesis specifically, absent for subtalar. No confidence intervals reported in the abstract and full text unreachable
• [256] Reaming-Induced Joint Surface Destruction in Tibiotalocalcaneal Nailing — Kalem, Balaban, Kısmet, Yılmaz, J Orthop Surg Res (2026-07-28). Cadaveric randomized study, 20 fresh-frozen limbs. Valgus-curved vs straight nails destroyed more calcaneal (12% vs 6%, p=0.018) and talar (15% vs 8%, p=0.007) posterior facet, with no difference at the talar dome or tibial plafond
• [257] Platelet-Rich Plasma in the Management of Foot and Ankle Pathologies — Foot & Ankle Specialist (2026-07-15). Narrative review, no level of evidence assigned. States the most consistent evidence supports PRP for plantar fasciitis and osteochondral lesions of the talus, with mixed results in Achilles pathology and ankle osteoarthritis. Added 2026-07-29; records a genuine tension with [248]
• [258] Concentrated Bone Marrow Aspirate in the Management of Foot and Ankle Pathologies — Foot & Ankle Specialist (2026-07-01). Narrative review. cBMA studied in talar osteochondral lesions, fracture healing and tendon disorders, but evidence heterogeneous and largely limited to small non-randomized studies; clinical role “not yet fully defined.” Added 2026-07-29
• [259] The Top 100 Most-Cited Publications on Osteochondral Lesions of the Ankle: A Bibliometric Analysis — J Exp Orthop (published online 2026-07-20), PMID 42519809. 69 of the 100 most-cited papers in this field are Level IV
• [260] Management of Ankle Osteoarthritis: Evidence-Based Clinical Practice Guideline — American Academy of Orthopaedic Surgeons, 50 pp. Adopted by the AAOS Board of Directors June 4, 2026; document states “Published 06/04/2026.” Read in full 2026-07-29 (previously cited on this page only via its press release). Intra-articular HA alone: Strong recommendation against, High quality of evidence; PRP not routinely suggested; no reliable evidence for intra-articular stem cell therapy. Contains the systematic review that reads Cohen 2008 as favouring saline
• [261] Anika Reports Second Quarter 2026 Financial Results — SEC Form 8-K Exhibit 99.1, filed 2026-07-29, accession 0001171843-26-004977, Item 2.02. “2027 Commercial Channel revenue guidance no longer includes revenue associated with Hyalofast”; FDA discussions “focusing primarily on the co-primary clinical endpoints” of the PMA; responses to a previously disclosed deficiency letter ongoing
• [262] Effects of Hyaluronic Acid With Intra-articular Corticosteroid Injections in the Management of Subtalar Post-traumatic Osteoarthritis — Randomized Comparative Trial — Gomes, Maranho, Gomes, de Castro, Mansur, J Foot Ankle Surg 2023;62(1):14-20. High-quality RCT; combination superior to corticosteroid alone for VAS pain at 1 month and AOFAS Total and VAS pain at 3 months. No placebo arm. Subtalar joint. Added 2026-07-29 from the AAOS evidence base
• [263] Dual Intra-articular Injections of Corticosteroid and Hyaluronic Acid Versus Single Corticosteroid Injection for Ankle Osteoarthritis: A Randomized Comparative Trial — Woo, Park, Park, BMC Musculoskelet Disord 2025;26(1):239. High-quality RCT; combination superior on AOS Total at 1.5 and 3 months. No placebo arm. Added 2026-07-29 from the AAOS evidence base
• [264] Diclofenac-Hyaluronate Conjugate (Diclofenac Etalhyaluronate) Intra-articular Injection for Hip, Ankle, Shoulder, and Elbow Osteoarthritis: A Randomized Controlled Trial — Kubo, Kumai, Ikegami, Kano, Nishii, Seo, BMC Musculoskelet Disord 2022;23(1):371. The third high-quality HA-versus-control ankle trial, previously missing from this page: reduced adverse events but no improvement in patient-reported outcomes. Added 2026-07-29 from the AAOS evidence base
• [265] Both MRI and CT Are Reliable and Valid in Evaluating Cystic Osteochondral Lesions of the Talus — Deng et al., Orthop J Sports Med 2020;8(9). 48 surgically-treated cystic OLTs. No significant difference between MRI and CT on depth (p=0.155), length (p=0.836) or width (p=0.711); interobserver ICC 0.935–0.999. Added 2026-07-29 — tempers the hope that a new CT would re-measure the 10 mm depth below the MASCOT 5 mm cap
• [266] Arthroscopic Bone Marrow Stimulation for Non-primary Osteochondral Lesions of the Talus Yields Limited Improvements Compared to Primary Lesions — Rikken, Dahmen, Hollander, Steman, Stufkens, Kerkhoffs, Foot Ankle Int (2026-02-24). Prospective, 2 years, 25 primary vs 19 non-primary (failed previous OLT surgery). Median NRS-walking improvement 3/10 primary vs 1/10 non-primary, p=0.01. Bears directly on MASCOT's bone-marrow-stimulation comparator arm for a revision lesion
• [267] Structural Distal Tibia Autograft for Large or Cystic Osteochondral Lesions of the Talar Dome — Kim, Haskell, Foot Ankle Int (2020), PMID 32088985. 32 patients; mean lesion area 86.2 ± 23.5 mm², mean depth 8.4 ± 3.0 mm. The closest published technical match to this lesion found anywhere, by a surgeon practising in San Carlos, CA
• [268] Malalignment and Osteochondral Lesions of the Talus on Standing Whole-Leg Radiography — Henkelmann et al., Osteoarthr Cartil Open (2025-11-19). 50 patients / 52 lesions, 83% medial. Malalignment associated with lesion side (p=0.024); varus correlated with medial lesions, OR 2.63, p=0.034
• [269] Effect of Coronal Alignment on Outcomes of Mosaicplasty for Medial Osteochondral Lesions of the Talus — Onder et al., J Foot Ankle Surg (2025-12-25). 44 mosaicplasties stratified by standing long-leg radiographs. Varus group post-operative VAS 4.4 ± 2.0 versus 1.5 ± 0.7 (p<0.001); mechanical-axis deviation versus post-operative VAS ρ = 0.804, p<0.001
• [270] Cystic Occurrence After Surgical Treatment of Osteochondral Lesions of the Talus — Dahmen, Hollander, Butler, Emanuel, Rikken, Stufkens, Kennedy, Kerkhoffs (2025-04-15). 13 studies, 382 ankles. Post-operative cysts in 42% after autograft, 58% after allograft, 34% after osteoperiosteal graft — with no relationship found between cyst presence and clinical outcomes
• [271] Second-Look Needle Arthroscopy After Prior Surgical Treatment for Cartilage Lesions of the Ankle: The Amsterdam and New York City Perspectives — Walinga, Butler, Dahmen, Stufkens, Kennedy, Kerkhoffs (2024-12-16). 16 patients, no complications observed. A lower-risk route to the containment question than a full diagnostic arthroscopy

July 30, 2026 Research Log [272-289]

Added by the sweep of July 30, 2026, covering items dated July 29–30 not captured in the four previous sweeps. The peer-reviewed window was almost empty; most of what follows is regulatory, payer or access material verified from primary sources — SEC filing exhibits, FDA device databases, published payer guidelines, statutory text and institutions' own pages. References [283]–[285] are older clinical papers added because they are candidate evidence exhibits for an insurance appeal, and [287] is added because it is the most revision-heavy talar allograft series in the United States.

• [272] Clinical Follow-Up 7–12 Years After Autologous Chondrocyte Implantation With a Hydrogel Scaffold (CaReS) in Knee Cartilage Defects — Wien Klin Wochenschr (2026-07-29), DOI 10.1007/s00508-026-02794-w. Level IV retrospective case series. 44 patients treated; score data rest on 12, MRI on 6. Lysholm 81.69 ± 11.39; MOCART 2.0 = 53.33 ± 17.51; satisfaction NRS 6.3, residual pain NRS 3.6. Knee; 73% attrition
• [273] Intra-articular Orthobiologics Show Statistically but Not Clinically Meaningful Improvements Compared With Viscosupplementation in Knee Osteoarthritis: A Network Meta-analysis of Randomized Controlled Trials — Arthroscopy (2026-07-29), DOI 10.1002/arj.70411. Level I, 24 studies, n=2,960. SUCRA ranking SVF > BMAC > UC-MSC > PRP > HA. “The magnitude of change in both pain and function did not exceed the minimal clinically important difference.” Knee
• [274] Vericel Reports Second Quarter 2026 Financial Results — SEC Form 8-K, accession 0001628280-26-050815, filed 2026-07-30. Revenue +22% to $77.5M; MACI +22.6% to $65.5M; FY guidance raised to $330–340M; first-ever $200M share repurchase authorization; MACI marketing authorization application submitted to UK MHRA. “MASCOT,” “talus,” “talar” and “osteochondral” appear zero times; “ankle” appears once, verbatim identical to the Q1 2026 boilerplate
• [275] Anika Therapeutics Form 10-Q for the quarter ended June 30, 2026 — SEC, accession 0001171843-26-005012, filed 2026-07-29. Confirms the Hyalofast PMA was submitted 2025-10-31 and the FDA deficiency letter received January 2026. Hyalofast clinical-study spend $275K vs $967K year over year (−72%); states “no material changes to the risk factors” despite removing Hyalofast from 2027 guidance. HYALOFAST is a Fidia Farmaceutici S.p.A. trademark licensed to Anika
• [276] Hyalofast Pivotal IDE Trial (NCT02659215) — n=200 actual, ACTIVE_NOT_RECRUITING, primary completion 2025-03-20. Co-primary endpoints: superiority over microfracture on percentage change in KOOS Pain and in IKDC Subjective at two years — both must succeed. Knee only, so talar use would be off-label even on approval
• [277] Patient Specific Talus Spacer (HDE H200001, Paragon 28 / Zimmer Biomet, approved 2021-02-17) — FDA Humanitarian Device Exemption record. Post-approval study status “Delayed”; 22 patients enrolled of a required 50. FDA safety summary: 7 serious adverse events in 5 patients, 5 probably device-related, and 14 subsequent secondary surgical interventions including 2 device removals and 7 reoperations. Follow-up 77.8% at 1 year, 38.5% at 2 years, 33.3% at 3 years
• [278] restor3d Total Talus Replacement (HDE H230003, approved 2023-11-17) — FDA record. Post-approval study “Delayed”; 3 patients enrolled of 50, at 1 site of a required 5. Indication explicitly covers “large, uncontained, unstable, or cystic talar osteochondral defects with risk of collapse or talar osteochondral defects not responsive to traditional treatments” — a labelled salvage route for this exact lesion type, on a very thin evidence base. The third talus device, 4WEB / Stryker H240001, has a post-approval study on Hold
• [279] Agili-C Cartilage Repair Implant (PMA P210034) — FDA. Applicant of record is Smith and Nephew, Inc., correcting this page's attribution to CartiHeal/Bioventus. Supplement S001 approved 2026-06-04, incorporating post-approval study clinical results into labelling. Indication remains knee-only: “ICRS grade III or above knee-joint surface lesion(s), with a total treatable area of 1-7cm², without severe osteoarthritis”
• [280] Carelon Medical Benefits Management Clinical Appropriateness Guideline MSK02-1125.1, Joint Surgery (effective 2025-11-15, current) — the guideline Anthem delegates cartilage surgery to. Patient Selection Requirements gate every procedure: “Disabling localized knee or ankle pain for at least 3 months, which has failed to respond to at least 6 weeks of conservative treatment”; significant impairment defined as “pain rated at least 3 out of 10 in intensity and associated with inability to perform ADLs and/or IADLs”; and “Normal alignment.” Talus autograft criterion requires no prior treatment or failed marrow stimulation; there is no talus allograft pathway; ACI in joints other than the knee is explicitly excluded
• [281] California DMHC Independent Medical Review Application (Form DMHC 20-224, Rev 09/24) — instruction sheet states verbatim: “If your plan denied your treatment because it was experimental/investigational, you do not have to take part in your plan's complaint or grievance process before you file an IMR application.” Free; decided in 45 days (7 if urgent); six-month filing window; the form states “approximately 72 percent of patients receive the requested service through IMR.” Help Center 1-888-466-2219
• [282] Foot and Ankle Outcome Score (FAOS) Scoring Guide — Roos et al. “A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.” Pain = 100 − (sum of 9 items × 100/36); Sport & Recreation = 100 − (sum of 5 items × 100/20). Added 2026-07-30 because the questionnaire URL previously used on this page now returns 404; a byte-verified archived copy of the instrument is linked in the July 30 log entry
• [283] Outcomes from Osteochondral Autograft Transplant or Mosaicplasty in 26 Patients with Type V Osteochondral Lesions of the Talus — Med Sci Monit (2021), PMID 34031353, open access. Added 2026-07-30 as a candidate appeal exhibit: the closest published match to this lesion's Hepple V staging
• [284] Allograft Versus Autograft Osteochondral Transplant for Chondral Defects of the Talus: Systematic Review and Meta-analysis — Am J Sports Med (2022), PMID 34554880, open access. Added 2026-07-30 as a candidate appeal exhibit
• [285] Fresh Osteochondral Allografts for Large-Volume Cystic Osteochondral Defects of the Talus — Raikin, J Bone Joint Surg Am (2009), PMID 19952243. n=15, mean lesion volume 6,059 mm³, AOFAS 38 → 83. Added 2026-07-30 as a candidate appeal exhibit for the cystic criterion specifically
• [286] Autologous Chondrocyte Implantation of the Ankle: 2- to 10-Year Results — Ferkel et al., Am J Sports Med (2014). Added 2026-07-30: cell therapy used as salvage after failed grafting in the ankle, by a surgeon verified as accepting new patients and listing Anthem Blue Cross (SCOI / UCLA Health, Van Nuys, 818-901-6600)
• [287] Midterm Prospective Evaluation of Structural Allograft Transplantation for Osteochondral Lesions of the Talar Shoulder — Duke (Easley, Adams, Nunley), Foot Ankle Int (2022), PMID 35502521. Added 2026-07-30: 74.2% of the cohort had prior ankle surgery — the most revision-heavy structural talar allograft series in the United States. Duke is also a MASCOT site
• [288] NYU Langone Orthopedic Second Opinion Service — $800 written second opinion, 5 business days, California eligible; records and imaging review with a detailed written report. Coordinator 646-878-1888; self-pay, FSA/HSA eligible. Relevant because John G. Kennedy, MD, Chief of Foot & Ankle at NYU Langone and the most-published author on failed talar osteochondral lesions, does not accept insurance — this route bypasses that. The service promises “an NYU Langone orthopedic surgeon,” not Kennedy specifically, so he must be requested by name
• [289] AOFAS 2026 Annual Meeting with IFFAS Program, September 16–19, Seattle — IFFAS Symposium 1, “Cartilage Lesions,” Friday September 18, 1:00–2:15 pm, with Eric Giza (MASCOT principal investigator) and John G. Kennedy speaking. Also “How Do I Get This Covered by Insurance?” and Samuel B. Adams on total talus. No patient or public registration category exists; the cheapest relevant tier is $750 and virtual costs the same as in person — but abstracts publish open access in Foot & Ankle Orthopaedics, and the plan documents count peer-reviewed abstracts from major medical meetings as acceptable appeal evidence

July 31, 2026 Research Log [290-300]

Added by the sweep of July 31, 2026. The peer-reviewed window was again nearly empty of ankle content, so the value this week came from three other places: the 2018 international consensus proceedings, which were retrieved in full open access from a university repository after the 2026 successor proved genuinely closed, and which have never appeared on this page despite being the most directly on-point documents in it; a set of older papers surfaced by re-indexing and verified to be months rather than days old; and a patient registry that fits this lesion's criteria. References [290]–[294] are the 2018 consensus set; [295]–[299] are clinical papers backfilled from earlier in 2025–2026.

• [290] Revision and Salvage Management: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Mittwede et al., Foot Ankle Int 2018;39(1S):54S–60S, PMID 30215315, DOI 10.1177/1071100718781863. Green open access via Amsterdam UMC repository; retrieved in full 2026-07-31. Eight statements with agreement percentages and evidence grades. Treatment failure defined at 1 year post-operatively (85%, B2); revision considered where a failed primary procedure is identified as the symptom source “in the absence of severe degenerative joint disease” (98%, B2); “any previously performed cartilage repair procedure may negatively impact the results of a subsequent revision procedure” (96%, B2); and the series' only unanimous (100%) statement — salvage is necessary for “a failed cartilage procedure that cannot be realistically addressed with a revision cartilage procedure” or progressive osteoarthritis. The trigger for fusion is joint condition and revisability, not the identity of the failed index procedure
• [291] Osteochondral Allograft: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Smyth et al., Foot Ankle Int 2018, PMID 30215308, DOI 10.1177/1071100718781097. Retrieved in full 2026-07-31. Fifteen statements. Bulk allograft for uncontained/shoulder lesions or those not addressable by autograft (94%, C); fresh non-frozen, size- and side-matched from the talus, not used if older than 28 days, preferably ≤21 days (98%, B2); 3D CT length/width/height most critical for size-matching (100%, unanimous); “a minimum of 10 mm of bone should remain on the bulk osteochondral allograft transplant” (86%, grade E) — a graft-construct specification, not an eligibility threshold, and not to be confused with the MASCOT 5 mm bony-defect exclusion or the Carelon 10 mm bone-defect criterion. Its own cited literature reports graft resorption or collapse in 56% and 67% of cases, in tension with the consensus calling collapse “rare”
• [292] Osteochondral Autograft: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Hurley et al., Foot Ankle Int 2018, PMID 30215309, DOI 10.1177/1071100718781098. Retrieved in full 2026-07-31. Fourteen statements. Autograft supported “in revision scenarios after a failed primary procedure with a lesion size more than 1 cm in diameter” (81%, B2); graft harvest length 12–15 mm (91%); congruency of the implanted graft essential (100%, unanimous); two grafts no worse than one but three or more may worsen outcome via donor-site morbidity (89%, B2); post-operative cysts common with unclear clinical significance (83%, C); donor-site morbidity generally <15% (91%, C)
• [293] Subchondral Pathology: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Shimozono et al., Foot Ankle Int 2018, PMID 30215311, DOI 10.1177/1071100718781866. Retrieved in full 2026-07-31. Nine statements. The hardest thresholds recorded on this page: “Lesions with a diameter >1 cm, depth >1 cm, and cysts >100 mm³ require bone grafting. For cystic lesions, bulk bone transplantation (eg, osteochondral autograft/allograft) should be considered” (91%, C). This lesion exceeds all three thresholds. Also: cancellous bone grafting preferred over bone-void substitutes (95%, C); symptomatic bone marrow oedema treated conservatively for at least 3 months (96%, E)
• [294] Scaffold-Based Therapies: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Rothrauff et al., Foot Ankle Int 2018, PMID 30215312, DOI 10.1177/1071100718781864. Retrieved in full 2026-07-31. Ten statements. Autologous chondrocyte implantation supported “in primary or revision procedures for large lesions greater than 1 cm², with or without cysts, including shoulder lesions” (80%, C); matrix-augmented bone marrow stimulation for primary and revision lesions >1 cm² and where bone grafting may be needed (92%, C); bone grafting considered at >3 mm bone loss measured intra-operatively after debridement (87%, E). Read alongside [292]: autograft and cell therapy are endorsed for this exact case at nearly identical agreement levels, on comparable evidence grades
• [295] Operative Treatment of Nonprimary Osteochondral Lesions of the Talus: A Systematic Review — Correia Cardoso, Andrade, Monteiro et al., Orthop J Sports Med (2024-12-03), PMID 39628764. 806 non-primary ankles — the largest revision-specific dataset recorded on this page. In the revision setting, osteochondral allograft and metal resurfacing showed lower effectiveness and higher failure rates, while autologous chondrocyte implantation and osteochondral autograft transfer both exceeded 80% success. Added 2026-07-31. Inherits the biases of the heterogeneous Level IV series it pools; comparisons are across studies, not within a trial
• [296] Clinical Assessment of the Missouri Osteochondral Allograft Preservation System: Lifelong Registry (NCT02503228) — University of Missouri-Columbia, observational, estimated 5,000 participants, started June 2015, estimated completion December 2050. Status ENROLLING_BY_INVITATION, single site. Conditions explicitly include the ankle; inclusion is an osteochondral defect ≥15 mm and age ≥13; the only exclusions are prisoners, workers' compensation cases and inability to consent — no revision exclusion. Verified from the registry API 2026-07-31. Two caveats recorded with it: the size criterion is written as measured “by MRI or diagnostic knee arthroscopy,” knee-centric wording needing clarification for an ankle; and the university settled lawsuits over its BioJoint knee surgeries, reported 2021. Missouri Orthopaedic Institute, 1100 Virginia Ave, Columbia MO; appointments 573-884-3077
• [297] Outcome After Mosaicplasty for Osteochondral Lesion of the Talus: 19 Patients, Over 10-Year Follow-up — Bister, Qadir, Repo, Haapamäki, Lindahl, Foot Ankle Surg (first published 2025-11-04), PMID 41203518, DOI 10.1016/j.fas.2025.11.003. All transfers incorporated; 89% satisfied or neutral; range of motion near-unchanged; authors support the technique for large talar defects “after failed nonoperative management or other operative treatment.” Only 53% retained the same osteoarthritis grade over the decade. Level IV, n=19, single centre — but the longest-horizon autograft data available in the revision population. Added 2026-07-31
• [298] Autologous Osteoperiosteal Transplantation From the Iliac Crest for the Treatment of Large Osteochondral Lesions of the Talus — Chen, Sun, Li et al., Int Orthop (first published 2026-04-13), PMID 41973114, DOI 10.1007/s00264-026-06807-1. Prospective single-arm, n=42, mean 32.5 months. VAS 4.36±1.76 → 0.45±0.63; AOFAS 75.38±13.52 → 95.33±4.81; second-look arthroscopy showed integrated cartilage-like tissue; no donor-site morbidity reported. Uncontrolled, single-centre — ankle series of this design systematically over-report. Its distinct value is avoiding harvest from a healthy knee. Added 2026-07-31
• [299] MRI Assessment of Autologous Osteochondral Transplantation in Talus: Correlation With Clinical Outcomes and Second Look — Liu, Chu, Zhou et al., Front Sports Act Living (first published 2026-01-29), PMID 41695604, DOI 10.3389/fspor.2025.1657265. 47 patients, all with second-look arthroscopy at 2 years. MOCART scores correlated poorly with both AOFAS/VAS function and arthroscopic ICRS grading. Practical consequence: a post-operative MRI is a weak proxy for how the ankle actually is, in either direction. Level III, n=47. Added 2026-07-31
• [300] MF-300 Phase 1, Epirium Bio (NCT07613684) — 100-subject Phase 1 completed October 2025, in muscle and ageing indications. Recorded 2026-07-31 as the current state of the 15-PGDH watch item: the programme has moved, but there is still no registered cartilage or osteoarthritis trial of a 15-PGDH inhibitor anywhere in the world, so the watch trigger has not fired. The underlying cartilage-regeneration science remains [173], a mouse and human-explant study of diffuse osteoarthritis rather than a focal defect over dead bone

August 1, 2026 Research Log [301-317]

Added by the sweep of August 1, 2026. The week's structural discovery is that the international consensus proceedings series is ten papers, not the five recorded last week — the five that were missing were retrieved in full open access and contain the highest-graded evidence on this site, including a Grade A1 statement that bears directly on the trial's bone-marrow-stimulation arm. A near-miss is recorded rather than buried: this sweep independently “rediscovered” the failed-talar-allograft revision literature and the Bugbee/Scripps recommendation and reported both as new. They were already on this site — see [190]–[196] and the revision allograft topic page — and those duplicates were removed before publication. References [301]–[306] and [315] are consensus papers; [307] and [312]–[313] and [317] are provider and access verifications; [308]–[310] are industry findings; [311], [314] and [316] are clinical papers new to this site.

• [301] Osteochondral Lesions of the Tibial Plafond (OLTPs): Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Rubin J et al. (44 authors), Foot Ankle Spec, online ahead of print 2026-07-31, PMID 42535925, DOI 10.1177/19386400261471631. Eleven statements, all strong consensus. Prognostic factors: lesion characteristics, cystic changes, kissing lesions, hindfoot alignment. Bone marrow stimulation for small non-cystic lesions; osteochondral transplantation for larger or cystic lesions; concurrent management of associated pathology. Paywalled — but the abstract confirms it re-publishes the 2019 meeting's consensus, whose full statements are open access at [302]. Level V
• [302] Osteochondral Lesions of the Tibial Plafond and Ankle Instability With Ankle Cartilage Lesions: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Dahmen J et al., Foot Ankle Int 2022, PMID 34983250, DOI 10.1177/10711007211049169. 43 experts, 2019 meeting. Retrieved in full 2026-08-01; the substantive open-access source for [301]. 11 plafond statements (4 unanimous) + 8 instability statements. Kissing lesions are a top-four prognostic factor at 100% agreement; “How should kissing lesions be managed? Simultaneously, with similar treatment principles applied for isolated lesions” (95%). On instability: “These should be managed simultaneously” (91%), single operation in all cases (88%), and the cartilage technique is unchanged by concurrent instability work (78%). For lesions >1 cm, “impact activities and shear stresses should be limited during the early rehabilitation period” (97%). Assigns no per-statement evidence grades — Level V throughout
• [303] Debridement, Curettage, and Bone Marrow Stimulation: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Hannon CP et al., Foot Ankle Int 2018;39(1S):16S–22S, PMID 30215307. Retrieved in full 2026-08-01. Fourteen statements. The highest-graded evidence recorded on this site: “The ideal size guidelines for use of bone marrow stimulation are lesions <10 mm in diameter, <100 mm² in area, and <5 mm in depth. Bone marrow stimulation is less likely to succeed when used as a sole treatment in a lesion 15 mm in diameter or greater” — 94% agreement, Grade A1 for diameter, A1 for area, B2 for depth. This lesion is 15 × 10 mm = 150 mm². Also: repeat marrow stimulation considerable where the primary was incompletely debrided or technically flawed (86%, B1); a prior marrow-stimulation procedure affects subsequent marrow stimulation and autograft but explicitly not allograft or scaffold-based therapy (72%, B2 — the weakest statement in the paper); cyst presence and previous cartilage repair both prognostic (92%, B2 each); debridement to 5 mm before bone grafting is required (77%, E)
• [304] Diagnosis — History, Physical Examination, Imaging, and Arthroscopy: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — van Bergen CJA et al., Foot Ankle Int 2018, PMID 30215306. Retrieved in full 2026-08-01. Twelve statements. Unanimous (100%), Grade B1: “Lesion size can be estimated in 3 planes… If precise measurement is required including depth, the use of CT is recommended. For daily practice, a size estimate using MRI is appropriate.” Paired with “Magnetic resonance imaging tends to overestimate lesion size” (89%, B1). Directly relevant to the MASCOT depth gate and contrary to this page's July 29 reasoning. Alignment appears in three separate statements — physical examination (98%), imaging documentation (96%, A2), associated conditions (98%, B1). CT in full plantar flexion for arthroscopic-accessibility planning (86%, A2). Diagnostic arthroscopy “is of limited value and seldom influences treatment approach” (88%, B1)
• [305] Rehabilitation and Return to Sports: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — D'Hooghe P et al., Foot Ankle Int 2018, PMID 30215313. Retrieved in full 2026-08-01. Nine statements. “Early weightbearing is beneficial, so long as shear forces are minimized… defined as beginning at 4 weeks postoperatively” — 87%, Grade A2, the strongest-graded statement in the entire series. Early motion within 1 week, no forced passive movement (98%, C). Shear forces limited 3 months; sport-specific training 3–6 months; return to competition 6 months to 1 year (92%, E). Clearance defined by “lack of negative effects with impact/loading” (88%, E), and imaging is explicitly not necessary for return-to-play clearance. Factors favouring return include lesion <1 cm² and a primary procedure (86%, C) — this case is unfavourable on both
• [306] Post-treatment Follow-up, Imaging, and Outcome Scores: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — van Dijk PAD et al., Foot Ankle Int 2018;39(1S):68S–73S, PMID 30215316, DOI 10.1177/1071100718781861. Retrieved in full 2026-08-01. Twelve statements. Subchondral oedema “may be seen on imaging for up to 2 years after treatment” in asymptomatic patients (91%, C), and “clinical function usually does not correlate with the appearance of post-treatment imaging except in cases where there is a mechanical cause” (82%, C). Radiographs after bone grafting or osteotomy; cross-sectional imaging only in symptomatic patients (88%, B2). Outcome scores at 3, 6, 12 and 24 months then annually (89%, E); longer follow-up specifically indicated for lesions >15 mm (82%, C)
• [307] Christopher D. Murawski, MD — Duke Health provider profile, verified 2026-08-01. Accepting new adult patients. Duke Sports Medicine and Orthopaedics Cary, 100 Duke Health Cary Pl; Duke Raleigh Hospital, 3400 Wake Forest Rd. 919-385-8120. Profile states a “particular interest in cartilage injuries (osteochondral lesions)” and that he “leads an international consensus on cartilage repair of the ankle.” Named author across the 2018 proceedings series including the revision and salvage paper [290]. Fellowship OrthoCarolina foot and ankle 2024; residency UPMC 2018–2023. Early-career — the field's consensus and literature specialist for this problem rather than a long operative track record. Blue Cross Blue Shield of North Carolina listed; Anthem not explicitly listed — verify. Duke is also a MASCOT site
• [308] Episurf Medical initiates dual-track process for its medtech operations — company release, 2026-04-20, verified 2026-08-01. The board mandated evaluation of “a sale of the medtech operations, a distribution of the operations to shareholders, and other measures,” with a solution to be identified no later than the end of 2026. The parent has since acquired over SEK 2bn of property portfolios. No statement anywhere in the June–August release run addresses Episealer Talus supply continuity, surgeon support, or the ongoing Episealer Talus study. Adds orphaning risk to an option already recorded here as never FDA cleared and Europe-only
• [309] Vericel Corporation Form 10-Q for the quarter ended 2026-06-30, filed 2026-07-30. Retains the full MASCOT program description verbatim — 309 subjects, 2:1 randomization to MACI versus arthroscopic bone marrow stimulation, two-year prospective multicenter open-label. Research spending rose to $7.5M in the quarter and $15.6M for the half, attributed in part to “MACI MASCOT trial spend.” Corrects the July 31 log's reading that the programme was winding down, which was inferred from softened earnings-call language; where a call's tone and a filing's contents disagree, the filing governs
• [310] Anika Therapeutics Q2 2026 results, 8-K Exhibit 99.1, filed 2026-07-29. New guidance policy driven by Hyalofast: “Given the timing uncertainty that remains in our regulatory review process, particularly as our discussions with the FDA on Hyalofast evolve, we are adopting a new revenue guidance practice. Going forward, our forecast will only include revenue from products that have received regulatory approval or clearance.” Management removing its own cartilage product from its own forecast. The US application is knee-only regardless. Recorded 2026-08-01 as grounds to retire Hyalofast as a watch item
• [311] Autologous Costal Cartilage Transplantation for Medial Osteochondral Lesions of the Talus: A Prospective Single-Arm Study With 2 Years of Follow-up — Du D, Zheng C, … Zhang C, JB JS Open Access, published 2026-04-07, PMID 41938050, DOI 10.2106/JBJS.OA.26.00024. n=28 (9F/19M), mean age 41.8. AOFAS 58.89±8.74 → 90.53±5.49; VAS 3.89±0.87 → 0.75±0.58; Tegner +1.96±0.69; MOCART 82.32±10.92 at 2 years. Complete defect filling in all 28; complete graft-bone integration in 25 (89.29%). The largest series of this technique, and specifically in medial lesions. Single-arm, single-centre, no comparator, no reported revision subgroup. Added 2026-08-01 — months old, surfaced through July news coverage rather than newly published
• [312] Duke Health Remote Second Opinion — verified 2026-08-01. $800, not covered by insurance; record gathering plus a written report delivered to the treating physician; available in all US states except Tennessee and Michigan, so California is eligible. A partner service contacts the patient within one business day. Two unresolved items: a 2022 Duke School of Medicine article describes the same programme at $1,500, so confirm the price before paying; and the service states it matches patients to “an appropriate Duke specialist,” so whether a named physician can be requested is unverified — ask for Murawski [307] explicitly. Duke general line 919-372-3584
• [313] EOS Imaging System — Stanford Health Care, verified 2026-08-01. Stanford's page states EOS “captures two full body, weight-bearing images of the skeletal system at the same time (one from the front and one from the side)” at significantly lower dose than conventional radiography — the hip-to-ankle mechanical-axis study this site has called its cheapest missing test, at roughly half the drive of the Fairfield unit. Unverified and requiring a phone call: which Stanford site houses the scanner, whether adults can be scanned, referral requirements, and cash price — the page publishes none of it. Radiology scheduling 1-866-742-4811. Candidate sites: Redwood City (450 Broadway), Hoover Pavilion Palo Alto, 451 Sherman Ave Palo Alto
• [314] Vascularised medial femoral condyle bone graft versus cancellous bone grafting for osteochondral lesions of the talus — Struckmann et al., J Foot Ankle Surg 2020;59(2):307–313, PMID 32130996. n=20 randomised. Vascularised graft VAS 5.2 → 1.0 and AOFAS 70.5 → 95.1 at 12 months, versus 6.6 → 4.0 and 71 → 84.1 for cancellous grafting. Related: Hintermann's series on free vascularised medial-condyle grafting for extended talar lesions (PMID 26330592). Requires a foot-and-ankle surgeon paired with a microvascular team; no United States centre performing it for the talus could be verified. Added 2026-08-01 as a named question for a consult, not a travel recommendation
• [315] Fixation Techniques: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Reilingh ML et al., Foot Ankle Int 2018, PMID 30215310. Retrieved in full 2026-08-01 for completeness of the ten-paper series. Fifteen statements. Relevant here: “There is no indication to perform fixation after a prior bone marrow stimulation procedure” (93%, C); and after failed fixation, marrow stimulation only for lesions <15 mm diameter, while “in larger defects, available options include osteochondral autograft, bone grafting, autologous chondrocyte implantation” (88%, E)
• [316] Failed osteochondral allograft of the talus converted to arthrodesis and subsequently to total ankle replacement — Juels et al., J Foot Ankle Surg 2020, PMID 31753570. Review plus case report; the fifth and last member of the failed-talar-allograft revision literature. Added 2026-08-01 for completeness of that set alongside [190], [191], [192] and [195], which have been on this site for months
• [317] Simon Görtz, MD — status resolved 2026-08-01 against the Massachusetts Board of Registration in Medicine public record and his Brigham directory listing. Massachusetts licence 279757, originally issued 2019-09-12, Active through 2028-01-11, no disciplinary entries; hospital affiliation Brigham and Women's. The 2019 issue date dates his move and makes the Phoenix trail stale rather than current. Directory lists him as accepting new patients. Brigham Orthopaedic and Arthritis Center, 60 Fenwood Road, 2nd Floor, Hale Building, Boston MA 02115; 617-732-4970; new-patient coordinator 1-855-278-8010. Still unresolved: whether he takes ankle cases — his Brigham profile names knee, shoulder and cartilage transplantation and contains “ankle,” “talus” and “talar” zero times, yet he co-authored the July 2026 ankle consensus with a Brigham affiliation. Trap recorded: a surgeon directory renders “Retired” on his entry inside a hidden conditional block that is not the live label — he is not retired, and automated reads of that page will get this wrong

August 3, 2026 Research Log [318-340]

Added by the sweep of August 3, 2026. Very little was published this week — the single in-window item is a correspondence exchange whose text cannot be retrieved. The value is in what chasing it surfaced: a 2026 Level 1 randomised trial and two phenotype-exact cohort studies [318]–[321], none previously held here, which together say the bone marrow stimulation arm is the wrong operation for a 15 mm cystic revision lesion. [322]–[326] are FDA adverse-event and tissue-safety records from the MAUDE pass the August 1 log left open. [327]–[328] and [339] are surgeon verifications; [329]–[332] are statutes and payer records that change how a second opinion can be obtained; [333]–[338] and [340] are access, registry and trial verifications.

• [318] A novel precision micro-drilling technique for treating osteochondral lesions of the talus with superior cartilage regeneration and early rehabilitation compared with microfracture: a randomized controlled study with 2-year follow-up — Li Y et al., J Orthop Translat 2026;56:101004, PMID 41836564, PMC12988511, open access, Level of evidence 1. Peking University Third Hospital, n=56 randomised 28/28. Full text retrieved and read 2026-08-03. FAAM-Sport improved 44.6% and 32.2% more than microfracture at 3 and 6 months (P ≤ 0.001), MOCART better at all follow-ups (P ≤ 0.002), but “after 12 months, there was no significant difference in clinical outcomes between the two groups.” The load-bearing content is the eligibility criteria: inclusion required “the diameter of OLTs smaller than 10 mm, the size of OLTs smaller than 100 mm², and the depth of OLTs smaller than 5 mm”; exclusions were “large cystic OLTs… history of surgeries… in the same lower extremity.” This lesion fails four separate criteria. The authors state their rationale verbatim: “OLTs larger than 100 mm² or those associated with large cysts… have a low success rate with BMS and generally require more aggressive treatments such as autologous osteochondral transplantation or autologous osteoperiosteal transplantation. Therefore, these patients were not included.” Enrolled lesions averaged 58.7 and 63.6 mm², under half of this one. Single centre, investigator-designed instruments, benefit gone by 12 months
• [319] Author's reply to the Letters regarding the micro-drilling technique — Li Y-b et al., J Orthop Translat art. 101181, DOI 10.1016/j.jot.2026.101181, Crossref-created 2026-07-31; with the Letter to the Editor it answers, DOI 10.1016/j.jot.2026.101180, created 2026-07-23. The only genuinely in-window item of this sweep, and its text could not be retrieved — absent from PMC and Europe PMC, Elsevier serves only a redirect shell, no OA copy exists. The substance of the criticism is unknown and nothing here should be read as knowing it. JOT is gold open access and the parent trial [318] is already in PMC, so a deposit should appear; recheck in 2–6 weeks
• [320] Medial Cystic Osteochondral Lesions of the Talus Exhibited Lower Sports Levels, Higher Cyst Presence Rate, and Inferior Radiological Outcomes Compared With Lateral Lesions Following Arthroscopic Bone Marrow Stimulation — Arthroscopy 2025;41(1):110–118, PMID 38797503, DOI 10.1016/j.arthro.2024.05.011. 31 matched pairs, ≥24 months. Medial lesions had significantly less improvement in FAAM daily-life and sport scores (P = .034, P < .001), lower MOCART (80.8 vs 86.0, P = .010), and a higher post-operative cyst rate (45.2% vs 16.1%, P = .013). On FAAM-Sport only 51.6% of medial versus 80.6% of lateral exceeded the MCID. A depth cutoff of 7.23 mm predicted post-BMS cyst presence. This lesion is medial and cystic. Level III, retrospective. Added 2026-08-03
• [321] Concomitant Subchondral Bone Cysts Negatively Affect Clinical Outcomes Following Arthroscopic Bone Marrow Stimulation for Osteochondral Lesions of the Talus — Arthroscopy 2023;39(10):2191–2199, PMID 37105367, DOI 10.1016/j.arthro.2023.03.029. 82 patients. Cyst group had greater depth (6.06 vs 3.96 mm, P = .000) and volume (248.3 vs 134.6 mm³, P = .002). Poor-outcome cutoffs after BMS: area 90.91 mm², depth 7.56 mm, volume 428.13 mm³. At ~150 mm² this lesion is 65% over the area cutoff — but the study only enrolled lesions under 100 mm², so the cutoff is extrapolated to him rather than measured on him. Level III. Added 2026-08-03. Independence caveat: [318], [320] and [321] all come from the same institution
• [322] FDA MAUDE report MDR 25635447 — restor3d Inc., CUSTOM TOTAL TALUS WITH TOTAL ANKLE, product code QNN, received 2026-06-26, event dated 2023-02-17, type Injury. Retrieved and quoted verbatim 2026-08-03: “THE PATIENT HAD A TALUS FRACTURE NONUNION WITH PREVIOUS TALAR REPLACEMENT… PATIENT HAS HAD TWO REVISIONS FROM A TOTAL TALUS TO A TOTAL TALUS WITH TOTAL ANKLE AND SUBTALAR FUSION. NOW, PHYSICIAN IS REVISING AGAIN WITH SPHERICAL-BOTTOM TALUS WITH TOTAL ANKLE AND STJ AND TN FUSION.” A fourth talus construct, with each revision consuming another hindfoot joint. The concrete mechanism behind this site's framing of total talus replacement as terminal rather than reversible. One case, filed 40 months after the event — not a rate
• [323] FDA MAUDE reports MDR 25394676 and 25394901 — 4WEB Inc. custom total talus, product code QNN, both received 2026-06-04, retrieved verbatim 2026-08-03. First: “EXPLANTED APPROXIMATELY SIX AND A HALF YEARS FOLLOWING THE INITIAL SURGERY… JOINTS AROUND THE IMPLANT ERODED CAUSING THE IMPLANT TO SHIFT OUT OF POSITION.” Second: explanted ~6 years post-op, “PATIENT REPORTEDLY PRESENTED WITH ARTHRITIS IN THE SUBTALAR AND TALO-NAVICULAR JOINTS.” Both replaced with another 4WEB device. Adjacent-joint degeneration is what both manufacturers' labels list as a contraindication — these reports show the implant producing it at roughly six years, the same order as this patient's own allograft survival. Product code QNN carries 18 reports all-time (3/2023, 5/2024, 6/2025, 4/2026) against a tiny installed base; a third 2026 report records explant at three months for wound-closure failure. A further five Paragon 28 reports received 2026-04-06 as a post-approval study dump include CRPS type 1 at 10 months and two anterior wound dehiscences within a month. Manufacturers uniformly concluded no device defect, and MDR counts cannot be made into rates for HDE products
• [324] FDA MAUDE report MDR 25243443 — Arthrex BioCartilage, received 2026-05-21. “INFORMATION HAD BEEN OBTAINED FROM A CLINICAL STUDY, A PILOT STUDY TO EVALUATE THE EFFICACY OF BIOCARTILAGE MICRONIZED CARTILAGE MATRIX IN MICROFRACTURE TREATMENT OF OSTEOCHONDRAL DEFECTS OF THE TALUS (US-01096).” Reported events: plantar-nerve and possible tarsal-tunnel involvement, bilateral neurological changes, an infected suture, a 40° gastrocnemius equinus contracture, and “A TOTAL OF FOUR (4) REOPERATIONS WERE REPORTED”; all assessed device-unrelated. A named, ongoing talus-specific Arthrex study that topic page 04 did not know existed. This is a manufacturer's aggregated safety filing, not a results publication. Added 2026-08-03
• [325] FDA MAUDE report MDR 24073226 — CartiHeal/Smith+Nephew Agili-C, received 2026-01-14. “THIS ADVERSE EVENT WAS ADDRESSED… BY REVISING THE TWO (2) AGILI-C IMPLANTS IN THE LATERAL FEMORAL CONDYLE, USING OSTEOCHONDRAL ALLOGRAFT. THE SURGEON NOTICED THAT THERE WAS VERY LITTLE CARTILAGE GROWTH OVER THE AREA.” Agili-C has 10 MDRs all-time, 3 in January 2026, concentrated in Failure to Osseointegrate, Fracture and Loosening. Knee, and the US label is knee-only — but an aragonite scaffold failing to integrate is on-point for any scaffold placed over sclerotic cystic bone, and this site's Agili-C coverage previously carried no safety signal at all. Added 2026-08-03
• [326] Important Information for Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) Establishments — FDA safety communication, page dated 07/16/2026, verified 2026-08-03. Asks establishments to consider, in the 21 days prior to recovery, donor diagnosis of or contact with Ebola disease or residence in an affected country. “Transmission of Ebola disease through use of HCT/Ps has not been described; therefore, the risk… remains theoretical” and “a donor screening test for Ebola disease is not available.” AATB responded 2026-07-17. Weighted low: advisory, theoretical risk, minuscule deferred population. Recorded as one more deferral layer on an already-thin fresh talar allograft pool, not as a supply event. Dating discrepancy: AATB says July 10, the FDA page says July 16
• [327] Kenneth J. Hunt, MD — UCHealth provider profile, verified 2026-08-03. UCHealth Foot and Ankle Center – Central Park, 3055 Roslyn St Suite 200, Denver CO 80238, 720-848-3668 (also Highlands Ranch 720-516-1000; Steadman Hawkins Englewood 303-694-3333). Fellowship completed 2009 — roughly seventeen years post-fellowship, against Murawski's 2024 [307]; appears four times as an author in the AOFAS 2026 final program, so currently active. Author of [328] and of a 2022 AOFAS series on articular regional reconstruction for large talar lesions with bony defects; co-author across the ICCRA consensus series. Three caveats recorded: his signature technique uses Cartiform, a viable osteochondral allograft membrane over morselised autograft — not the bulk fresh talar allograft that failed here in 2012, so whether he performs bulk revision OCA is an open question; the profile does not state whether he is accepting new patients; and it contains the words talus, talar, osteochondral and allograft zero times — his credentials come from the literature, not the page. Licence standing unverified: the Colorado DORA and California DCA lookups are both CAPTCHA-gated and were not bypassed
• [328] Management of Treatment Failures in Osteochondral Lesions of the Talus — Hunt KJ, Ebben BJ, Foot Ankle Clin 2022, PMID 35680295. Literally the title of this problem, and the basis for adding [327] as a surgeon candidate. Added 2026-08-03
• [329] California Health & Safety Code §1383.15 — second opinions. Fetched and quoted 2026-08-03. “When requested by an enrollee or participating health professional who is treating an enrollee, a health care service plan shall provide or authorize a second opinion.” Qualified means a professional “who possesses a clinical background, including training and expertise, related to the particular illness, disease, condition.” Decisively: “If there is no participating plan provider within the network who meets the standard specified in subdivision (b), then the plan shall authorize a second opinion by an appropriately qualified health professional outside of the plan's provider network.” May convert the $590–$1,690 cash second-opinion field into a covered authorisation, and is the cleanest on-ramp to the out-of-network authorisation this site already wants. Applies only to Knox-Keene plans — see [330] for the 60-second test
• [330] California continuity of care — Health & Safety Code §1373.96 (DMHC plans) and Insurance Code §10133.56 (CDI PPO policies), fetched 2026-08-03; one of the two applies under either regulator. A serious chronic condition qualifies for up to 12 months past contract termination; separately, a “surgery or other procedure… authorized by the plan as part of a documented course of treatment and… recommended and documented by the provider to occur within 180 days” of termination is protected at contracted rates. The enrollee must request it — it is not automatic. Related: §1368.02 requires Knox-Keene plans to print the DMHC notice in 12-point boldface naming 1-888-466-2219, which is the test for which regulator governs the plan — a California Department of Insurance notice (1-800-927-4357) instead means CDI, and neither notice means self-funded ERISA
• [331] ERISA document demand — 29 U.S.C. §1024(b)(4) and §1132(c)(1), fetched 2026-08-03. “The administrator shall, upon written request of any participant or beneficiary, furnish a copy of the latest updated summary, plan description, and the latest annual report… the bargaining agreement, trust agreement, contract, or other instruments under which the plan is established or operated.” §1132(c)(1) makes an administrator who fails to mail the material “within 30 days after such request… personally liable… in the amount of up to $100 a day.” Converts the employer self-funded question — unresolved for four sweeps and blocking three separate recommendations — from a document-reading task into a letter with a statutory deadline. Free. Parallel corroboration route: DOL EFAST2 Form 5500 search, line 9a distinguishes Insurance from General assets of the sponsor; small plans are exempt from filing and filings lag ~1 year
• [332] Scripps Health – Anthem contract negotiation status, page marked updated 2026-07-30, verified 2026-08-03. The extension “is set to expire on September 30, 2026,” negotiations continue, and Scripps states “Anthem has not agreed to fair payment and reduced bureaucracy.” Genuinely unresolved with 58 days to run. Bugbee's own Scripps profile states “In-person visits only” — no video visit and no online scheduling, so there is no remote shortcut — and lists osteochondral allograft transplantation among his procedures while never using the word “talus.” Scripps has no remote written second-opinion program; its only virtual care is E-Visit and Video Visit for established patients
• [333] ICRS Patient Registry — re-verified 2026-08-03, and the negative recorded on 2026-08-01 still holds: the registry “is currently available for knee problems, but other joints will be added in due time.” The five-minute task now has an address: registry@cartilage.org, cc theodorakys.marin@cartilage.org (Dr. Theodorakys Marin Fermin, Patient Registry Manager), to ask when the ankle module goes live and whether a revision talar OCA patient can pre-register
• [334] AOFAS 2026 Annual Meeting final program — public, free, no login; retrieved 2026-08-03. The meeting was already recorded on this site; the abstracts were not. Four are squarely on this case: “Mid-Term Outcomes of Repeat Arthroscopic Bone Marrow Stimulation for Secondary Osteochondral Lesions of the Talus” (Lee et al.); “Sustained Improvement in Pain with Talar OsteoPeriostic Grafting from the Iliac Crest (TOPIC) for Medial OLT” (Hollander, Kerkhoffs, Dahmen, Stufkens — the Amsterdam group behind topic page 26); midterm particulated juvenile cartilage allograft outcomes (Rajan, Day, Schon); and an RCT of umbilical-cord allogeneic MSCs with microfracture (Protasowicki et al., IFFAS Award finalist). Session 1B is moderated by John G. Kennedy. Unpublished data with named authors — usable as specific consult questions and as a Q4 publication watch list. Meeting Sept 16–19, Seattle
• [335] PMID 42522736 — the free PubMed handle for the ICCRA consensus on moderate-to-large 1–2.9 cm² lesions already held here as [247]. Recorded 2026-08-03 for one reason: the August 1 log called that paper “proven closed on eleven retrieval routes,” which remains true of the full text (Unpaywall re-checked 2026-08-03: is_oa: false, oa_status: closed, 0 oa_locations) — but its complete structured abstract has been freely readable in PubMed since 2026-07-29, and PubMed was not among the eleven routes. Nothing substantive was missed because this site already holds the abstract content via Crossref. Also recorded as a dedup near-miss: one research line reported this paper as absent and “the single most on-point reference yet”; the grep found it on three files. The line that had read the site was right; the line that had read only the logs was wrong
• [336] Editorial Commentary: Cartilage Restoration Is Joint Preservation, and Joint Preservation Requires Treating the Whole Joint — Ackermann J, Friedman L, Sassower A, Cole BJ, Arthroscopy, 2026-07-31, in-window, PMID 42535506. Knee-only — it names malalignment, meniscal deficiency, ligamentous instability and patellofemoral maltracking, with no ankle content. Its one transferable claim is that progress “will require… long-leg alignment imaging,” reframing concomitant procedures “from add-ons into graft-protecting interventions” — converging with this site's standing alignment-film recommendation from a fourth independent direction. Recorded at low weight and explicitly not citable as ankle evidence
• [337] CurveBeam AI facility locator — checked 2026-08-03, and it corrects a statement in this site's Next Steps tab that Burlingame is the only weight-bearing CT in Northern California. The locator also lists PACE Podiatry and Ankle Care / Steven K. Shoemaker, DPM, 1421 Secret Ravine Pkwy Suite 111, Roseville CA 95661, 916-781-3223. Their own website is now a parked domain and the cash price is unpublished — call before driving. Also confirmed: no CurveBeam HiRise (the hip-to-ankle weight-bearing unit) anywhere in Northern California; nearest is Orthopaedic Institute for Children, Los Angeles
• [338] ACTRN12624000412538p — “Efficacy of Viable Cartilage Allograft in talar osteochondral lesions,” Sydney Orthopaedic Foot and Ankle Research Institute, NSW. Registered 2024-04-04, still Not yet recruiting, ethics Submitted, not yet approved, flagged Not up to date. Not eligible: exclusions are “bilateral surgery, revision procedures, not willing to participate.” Contact Rajat Mittal, +61 2 8755 2645. Recorded because it is the closest analogue anywhere to a trial of exactly this lesion, and he is barred from it. Companion: ACTRN12619000688189p (MALT, Wellington NZ), microfracture vs JointRep, ethics “not yet submitted” seven years on and effectively dead; excludes “Previous ankle operation” and bipolar lesions. These are this site's first non-NCT registry identifiers; ANZCTR was recorded as automation-blocked for four sweeps and is not — its 403 is Cloudflare interstitial, which a real browser clears
• [339] Bipolar Fresh Osteochondral Allograft Transplantation of the Tibiotalar Joint: A Concise Mid-Term Follow-up — French MH et al. (incl. Brage and Bugbee), J Bone Joint Surg Am 2019, PMID 31045670. Added 2026-08-03 alongside a surgeon check on Michael E. Brage, MD, Sigvard T. Hansen Foot and Ankle Institute, Harborview, 908 Jefferson St, Seattle WA 98104, 206-744-4830 — Bugbee's and Görtz's actual co-author on five fresh-ankle-allograft papers 2002–2019. Recorded rather than recommended: his allograft work is bipolar tibiotalar shell allograft for ankle arthritis — whole-joint resurfacing, which is the escalation path rather than the focal talar graft under consideration. His UW faculty profile returns HTTP 500 and a PeaceHealth Bellingham listing also exists, so confirm location before booking travel
• [340] California Business & Professions Code §2472(b) with 17 CCR §30441 — fetched 2026-08-03, and together they explain a stall this site never diagnosed. §2472(b) limits podiatric practice to “the human foot, including the ankle and tendons that insert into the foot”; a hip-to-ankle mechanical-axis study images the femur and hip, outside DPM scope. 17 CCR §30441 requires radiologic procedures to be “prescribed by a licentiate of the healing arts” — there is no self-referred X-ray in California. The alignment film has been an action item since July and has never been taken; Dr. Salk cannot order it. It needs an MD or DO — or, per NorthBay's own EOSedge page, a chiropractor's referral, walk-in and no appointment. Verified cash prices for CPT 77073: NorthBay $2,057 (the best-matched machine, and the worst price found), against UC Davis $252.80, John Muir $305.77, ZSFG $345, UCSF $516.60 all-in, Stanford $736.40. Flagged as needing confirmation: a UC Davis machine-readable file lists an Anthem PPO negotiated rate of $33.57 for 77073, which if it holds would invert this site's assumption that an unmet deductible makes cash-pay equivalent — not independently re-extracted, and excludes the radiologist read. Confirmed 2026-08-04 — see [346].
• [341] FDA recall Z-2758-2026, Paragon 28, Inc. — re-pulled directly from openFDA and verified 2026-08-04. Class II, status Ongoing, report_date 2026-07-29, initiated 2026-06-17. Product: “P28 PHANTON INTRAMEDULLARY NAIL SYSTEM, Phantom Hindfoot TTC/TC Ball Tipped Guide Rod… provides stabilization of the hindfoot and ankle.” Reason: “Paragon 28 received two (2) complaints… involving breaches in the sterile barrier of the pouch packaging.” 514 units, distributed US nationwide plus Australia, Canada, the Netherlands and New Zealand. Read it correctly: this is instrumentation for tibiotalocalcaneal fusion — the end-stage branch — and it is a packaging defect, not a design or material failure. It says nothing against the implant or the operation. Recorded because it is the only in-window regulatory action anywhere that touches hindfoot and ankle hardware, and because a sterility recall is a scheduling risk worth one question if fusion hardware is ever actually being booked
• [342] FDA MAUDE report MDR 24492416 — 4WEB Inc., product code QNN, date_received 2026-03-02, event dated 2025-12-01, Injury. New to this site 2026-08-04. Verbatim: “A 4WEB CUSTOM-MADE DEVICE WAS EXPLANTED APPROXIMATELY THREE MONTHS FOLLOWING THE INITIAL SURGERY… TISSUE CLOSURE COMPLICATIONS AND A DELAYED WOUND. THE 4WEB DEVICE WAS EXPLANTED… AND REPLACED WITH AN ANTIBIOTIC SPACER.” Out of window but previously unlogged, and it completes the 2026 QNN picture: three of the four total-talus adverse-event reports filed in 2026 involve 4WEB devices — one explanted at three months for wound failure, two at roughly six and six-and-a-half years for adjacent-joint erosion. Against this patient's own 12.4-year allograft, the metal-talus salvage route looks worse on durability, not better
• [343] Smith+Nephew H1 2026 results, Form 6-K filed 2026-08-04 (accession 0001104659-26-089991), existence confirmed 2026-08-04 against the SEC submissions API. On Agili-C, which sits on this patient's option list: the implant “delivered strong growth as we continue to expand availability, including completing first cases in Europe and Australia,” and the company reports “announcing new clinical data supporting adoption of our REGENETEN and CARTIHEAL AGILI-C implants.” Weighted low, and the caveats matter more than the headline: the filing contains no ankle or talus indication and announces no US label change — Agili-C's US label remains knee-only — and commercial expansion is not clinical evidence. Read alongside [325], which records Agili-C's failure-to-osseointegrate signal. Smith+Nephew also cut FY26 sales-growth guidance from 6% to 4%
• [344] FDA 510(k) K262294 — Philips Medical Systems Nederland, decision date 2026-07-24, product code MOS: dS FootAnkle 16Ch 1.5T and dS FootAnkle 16Ch 3.0T. Dedicated 16-channel foot-and-ankle MRI receive coils at both field strengths. Recorded at low weight and only because of what this site has already documented: the central open question here is a measurement dispute — a 10 mm cyst depth from a remote records review against “up to 4 mm” on the patient's own CT — and coil quality is a standard driver of disagreement in ankle cartilage MRI. This is not a reason to re-scan; it is context for why two readers of the same ankle can differ
• [345] Mark C. Drakos, MD — Hospital for Special Surgery, New York. Verified from his HSS profile 2026-08-04, and the best new surgeon name of this sweep. Specialties listed as Foot and Ankle Surgery and Sports Medicine Surgery; the profile explicitly lists “Cartilage Injuries” among conditions treated and “Cartilage Repair” among procedures, and his active research includes “Evaluation of Biocartilage Allograft Matrix for the Treatment of [talar] Osteochondral Lesions.” Crucially for a California patient, the profile states “Offers Virtual Care.” 535 East 70th Street, New York, NY 10021 — 212-606-1112. Fellowships: HSS sports medicine 2009, Brown foot and ankle 2010, so roughly sixteen years post-fellowship. Two honest caveats: the page does not state whether he is accepting new patients, and HSS's separate remote second-opinion programme excludes California — so “offers virtual care” must be tested against state licensure before assuming a video consult is possible. Ask directly whether a California resident can have a virtual new-patient visit, and if not, whether records can be reviewed ahead of an in-person visit
• [346] UC Davis Medical Center hospital price-transparency machine-readable file (CMS schema v3.0.0, last_updated_on 2026-04-01) — downloaded and parsed 2026-08-04. This confirms the item [340] flagged as unverified. For CPT 77073 (“X-rays bone length studies”), outpatient, billing class facility: payer Blue Cross, plan “Ucd Hb Blue Cross Ppo”, methodology fee schedule, standard_charge_dollar $33.57 — against a discounted cash price of $252.80 and a gross charge of $632. The caveat is component scope, and it is important: $33.57 is the hospital facility/technical charge only. Hospital files never include the medical-group professional claim, so expect a separate radiologist read (77073-26) on top — small, on the order of $10–20 by Medicare's professional component, but unverified. There is no additional facility fee beyond this line. Practical effect: the single most-recommended missing test on this site should cost about thirty-five dollars plus a small read at UC Davis, not the $2,057 NorthBay charges cash
• [347] Routes to actually get the alignment film ordered — both verified 2026-08-04, and together they close an action item that has sat open since July. NorthBay EOSedge states verbatim: “ask your doctor or chiropractor for a referral” and “No appointment needed, just walk in.” NorthBay Health Imaging, 1101 B. Gale Wilson Blvd., Fairfield CA 94533, (707) 646-4646, referral fax (707) 646-4949, Mon–Fri 8–5. Since a California chiropractor may order radiographs, a cash DC visit legally generates the order that [340] shows Dr. Salk cannot write — but NorthBay's cash price for 77073 is $2,057, so confirm the Anthem negotiated amount with NorthBay billing before walking in. UC Davis Radiology requires “a written request from your physician,” and plain radiography is walk-in “Monday–Friday, 8 a.m.–5 p.m.”; scheduling 916-734-0655, order fax 916-703-2254. Unverified: whether UC Davis accepts orders from non-UC-Davis community physicians — confirm by phone before faxing
• [348] Diagnostic Orders Direct state availability — checked 2026-08-04 and recorded as a closed route. This $40 telehealth service issues imaging orders without a primary-care visit, which would have solved the ordering problem outright. California is not among its states. The 30 states plus DC listed are AK, AZ, CO, CT, DE, DC, FL, HI, ID, IA, KS, ME, MD, MA, MN, MT, NE, NV, NH, NM, NY, ND, OK, OR, RI, SD, UT, VT, WA, WY. Eligibility is “based on where the patient is physically located at the time of the virtual visit,” so it would only work from out of state. Recorded so a future sweep does not re-chase it
• [349] Total ankle replacement versus ankle fusion for end-stage ankle osteoarthritis: a narrative review of the latest literature data (2023–2025) — EFORT Open Reviews, PMID 42546056, DOI 10.1530/EOR-2025-0106, in-window, created 2026-08-03. Abstract retrieved and verified directly from PubMed 2026-08-04; full text paywalled. “A prospective multicentre study with level II evidence found that the long-term clinical results of TAR and AF were similar… A meta-analysis identified TAR as the superior intervention… TAR had notable lower total complications, implant removals, adjacent level fusion surgeries, and non-union… surgeries after the index procedure.” And the conclusion: “The existence of mixed evidence… makes it necessary to select the surgical technique… on an individual basis.” This is end-stage salvage, which is exactly where this patient is not — and it is a narrative review with no pooled numbers and no stratification for post-traumatic arthritis under 40, the only subgroup that would describe him. Its use here is defensive: after three systematic reviews and a meta-analysis the field still cannot name a winner, so “we will just fuse it eventually” is not an evidence-backed default. It also reports that “racial/ethnic, socioeconomic, and payer status disparities have been reported in the likelihood of experiencing TAR versus AF”
• [350] Minced cartilage implantation for cartilage regeneration: a survey of current clinical practices — Arch Orthop Trauma Surg, PMID 42545542, DOI 10.1007/s00402-026-06443-9, in-window, 2026-08-03. Abstract read 2026-08-04. A survey of all 4,915 members of the German arthroscopy society, 927 responses, 19% response rate, fielded January–February 2024. “MCI has emerged as one of the three most commonly used cartilage repair techniques in the knee joint. Defect sizes up to 4 cm² represent the largest treated group… The application of the procedure is quite heterogeneous, with some practitioners using a shaver and others manually mincing with a scalpel.” Knee only, no ankle data, no outcomes — it measures what surgeons say they do, not whether it works. Recorded against topic page 07 for one narrow reason: minced and particulated cartilage has crossed into routine European knee practice while the talar evidence has not moved, and the technique is not standardised even where it is popular
• [351] Richard D. Ferkel, MD — SCOI physician page, re-verified 2026-08-04, and this entry exists to kill a false alarm. A search-result aggregator surfaced during this sweep flagged his California licence as “expired 2026.” The primary source does not support that. scoi.com returns HTTP 200 today and states that “Dr. Ferkel is available to see patients at the Van Nuys and Westlake offices” and that he “is currently the director of the sports medicine fellowship program” at SCOI, with an active appointment request form and phone 818-901-6600. He is recorded as active. This matters because he remains the only surgeon found anywhere with both “accepting new patients” and “Anthem Blue Cross” verified on the same institutional page. One caveat this site has not previously stated: SCOI bills him as a “Fellowship-Trained Sports Medicine, Reconstructive Knee, and Shoulder Surgeon” whose foot-and-ankle credential came as “additional training in foot and ankle surgery” alongside that fellowship — so his ankle standing rests on his publication record [286], not on how SCOI markets him
• [352] NCT07332182 — “MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee,” Fin-Ceramica, registered 2026-01-12, Not yet recruiting. Criteria pulled from the registry API and read in full 2026-08-04. He is not eligible — it is knee-only (“lesions localized in femoral condyles and/or trochlea”). It is recorded for one reason, and it is a genuinely useful one. Exclusion 5 reads: “Bony defect depth deeper than 5 mm, according to baseline MRI, measured from the original subchondral bone plate level.” That is the same 5 mm cap MASCOT applies — in an unrelated trial, by a different sponsor, for a different product class (an osteochondral scaffold rather than a cell therapy), in a study whose own title advertises it as treating deep lesions. So the 5 mm gate is an industry-wide convention, not a Vericel quirk, and it will follow him across sponsors. It also supplies the measurement definition MASCOT's record never states — depth from the original subchondral bone plate level — which is exactly the question this site has been telling him to put to a radiologist
• [353] jRCT (Japan) and ChiCTR (China) — closed 2026-08-04 after four sweeps as genuinely unobserved registries. Neither is a JavaScript shell in the way earlier logs assumed. jRCT searches by POST but its result pages expose GET parameters including sort=record_cert_date; driven through the form by hand rather than bulk-scraped, per jRCT's own terms of use. talus 1 record (last modified 2020-12-21); 距骨 5, newest 2025-01-06; osteochondral 3, all knee. ChiCTR's block is an Aliyun WAF JavaScript challenge, not a shell, and its search fires from a div rather than a submit button — which is why URL parameters never filtered. talus 10 records, newest registered 2025-12-31. Zero in-window relevant records in either. Controls prove both negatives real: jRCT returned five genuine in-window records (limb revascularisation and achondroplasia, 07-29 to 07-31) and ChiCTR's unfiltered listing is current to 2026-08-04 across 127,048 trials. One standing lead, out of window: jRCTs062260036, an articular cartilage regeneration study listing “Knee osteoarthritis, Ankle osteoarthritis,” recruiting, last modified 2026-07-03 — Japan-only, and osteoarthritis rather than a focal lesion
• [354] CTIS (EU Clinical Trials Information System) — correctly callable as of 2026-08-04, and its four prior recorded zeros were artifacts. The August 3 log identified the wrong HTTP verb as the problem; that was only half of it. A POST carrying searchCriteria alone returns totalRecords: 0 for every query, including a blank one — a silent false zero. The working request nests pagination and sort inside the body alongside searchCriteria. Controls: a blank search returns 12,150 trials, with 38 in-window decisions in the top 200 by date; term totals cartilage 21, ankle 30, chondrocyte 3, talus 1, talar 0, osteochondral 0. One in-window record exists in the whole of Europe and he is not eligible for it: 2026-526179-49-00 (2026-08-03, Freiburg) — autologous minced cartilage implantation versus matrix-associated ACI for “Full-thickness cartilage defects of the knee.” Companion correction: ISRCTN's date bug is worse than previously recorded — the native format returns the entire 28,517-record database for an impossible date too, its WHO format carries no lastUpdated field at all, and offset is silently ignored, so the 100-record cap cannot be paged around. Only complete narrow topical subsets, filtered client-side, are valid
• [355] Mass General Brigham Online Second Opinions — contact detail added 2026-08-04 to an option this site already prices at $950 plus $375 per imaging study. The programme states that “no matter where you are located, you are connected to the Mass General Brigham physicians,” and it is physician-to-physician — “you and your doctor register and send all your case material” — so Dr. Salk would be the initiating clinician. Contact: 888-456-5003, consultsinfo@partners.org. Flagged unverified: the current price could not be re-confirmed this sweep because the intake portal returned a TLS error, and whether a podiatrist may serve as the initiating physician is unconfirmed — both are one phone call. Also closed this sweep: Mayo Clinic has no patient-initiated written remote second opinion, and its virtual care is available out of state “only if the provider is licensed in the state where the patient lives,” so there is no California route
• [356] NCT03588975 — “A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee,” lead sponsor Vericel Corporation, Recruiting. Criteria pulled from the registry API and read in full 2026-08-05. This single record falsifies the claim this site published on August 4 that the 5 mm bony-depth cap is an industry-wide convention. Its inclusion criteria admit “at least 1 defect size ≥1.5 cm²… defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.” Same company, same cell therapy, a different number — so 5 mm is a per-protocol design choice, not a rule Vericel applies to itself universally, and certainly not a convention of the field. He is not eligible for this study (knee, ages 10–17); it is recorded solely as the disproof
• [357] NCT03299959 — “Agili-C™ Implant Performance Evaluation,” pivotal IDE, lead sponsor Smith & Nephew, Completed. Read from the registry API 2026-08-05. Exclusion 2: “Bony defect depth deeper than 8mm, according to baseline MRI/X-ray/arthroscopy.” Sixty percent more permissive than MASCOT's cap for an implant that is likewise not a bone graft. Read together with [356], the observed caps across the registry run 2, 3, 4, 5, 6, 7 and 8 mm, which is a distribution of device-specific engineering limits rather than a shared threshold. Recorded against [352], whose generalisation this corrects
• [358] NCT06527482 — “Autologous Osteoperiosteal Transplantation for the Treatment of Severe Osteochondral Lesions of the Talus,” Beijing, China, listed Recruiting. Full criteria read 2026-08-05, inclusions and exclusions separately. Inclusion: “Hepple V OLT on the medial side of the talus or the diameter of the lesion ≥ 8 mm” after at least three months of failed conservative treatment. The complete exclusion list — varus/valgus over 5°, grade III lateral ligament injury, chronic synovitis, joint fibrosis, knee osteoarthritis, rehabilitation non-compliance, unfitness for surgery, pregnancy — contains no depth cap and no prior-surgery or revision exclusion of any kind. This is the registry anchor that topic page 26 has discussed AOPT without ever having. Two limits, stated plainly: it is China-only, and its record has not been updated since 2024-08-06, so the “recruiting” status is two years stale and should not be relied on. Its value is as evidence about how bone-carrying techniques treat depth, not as an enrolment option
• [359] NCT05942430 — “Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions,” Guangzhou, China, listed Recruiting. Criteria read in full 2026-08-05. Inclusion: “Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points” after six months of failed conservative care. Depth here is the indication, not the disqualifier — the mirror image of MASCOT's exclusion 1, at the identical number. A second detail matters independently: inclusion also requires “Unilateral talar osteochondral lesions without corresponding lesions on the tibial side” — making this the second trial whose eligibility turns on the unanswered kissing-lesion question in action item 11. China-only, and the record has not been touched since 2023-09-06
• [360] Conservative Management and Biological Treatment Strategies: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle — Dombrowski, Yasui, Murawski, Fortier, Giza, Haleem, Hamid, Tuan, Zhang, Schon, Hogan, Foot Ankle Int 2018;39(1_suppl):9S-15S, PMID 30215314, DOI 10.1177/1071100718779390. This site held ten of the eleven papers in the 2017 consensus series; this was the missing one, and it is the only one covering conservative and biological management — the branch this patient is in today. Found by a series-completeness check, which is a class of gap a date-windowed sweep structurally cannot surface. Paywalled at SAGE; full text retrieved 2026-08-05 as the publisher's version from the Amsterdam UMC repository (the /ws/files/ path form). 75 experts, 25 countries, Delphi method, 12 statements, 10 at strong consensus. The load-bearing statement is one where the omission is the finding. The question named HA explicitly — “Can the injection of a biological product (eg, cBMA, HA, PRP, adipose, etc) be considered as a conservative management strategy…?” — and the agreed answer named only two: “The injection of a biological product in the form of concentrated bone marrow aspirate or platelet-rich plasma can be considered… if there is no improvement in symptoms after 4-6 weeks.” Stated with its limits: this was the paper's weakest vote at 61% agree / 39% disagree — bare consensus on its own 51–74% scale, not the strong consensus most statements reached — graded B1, and it is 2017 work that predates the ankle HA-versus-saline trials recorded on topic page 02. It is an omission, not a condemnation, but it is an omission by the largest panel ever convened on the question. Two errata exist (Foot Ankle Int 2021;42(2):248 and 2022;43(1):NP3) and should travel with the citation
• [361] Favorable Short-Term Outcomes of Matrix-Associated Autologous Chondrocyte Implantation for Osteochondral Lesions of the Talus: A Systematic Review — Wen, Syed, Ansari, Thomas, Shehabat, Akhtar, Razick, Kreulen, Arthroscopy 2025 Dec;41(12):5492-5502.e1, PMID 40972779, DOI 10.1016/j.arthro.2025.07.045. Added 2026-08-05 to close a gap this site created for itself: the Next Steps tab has been telling him to call Dr. Kreulen partly because he was senior author on this review, while the review itself was cited nowhere and its numbers had never been read. Senior author is at the UC Davis Department of Orthopaedic Surgery, Sacramento — the only West Coast MASCOT site — and MACI is the MASCOT intervention. 11 studies, 166 patients total, ages 17.7–45.8 (he is 30), defect sizes 1.21–3.4 cm² (the floor is essentially MASCOT's 1.2 cm² threshold), follow-up 21–144 months. AOFAS 36.9–70.1 pre → 78.3–95.3 post; return to sport 50–82.4%. Read the harms honestly: complications 0–59% and revisions 0–45%, and “no included studies reported minimal clinically important difference, patient acceptable symptom state, or substantial clinical benefit metrics, limiting the interpretation of patient-level clinical improvements.” Level IV. 166 patients worldwide is a thin base for the intervention the top-priority trial is testing, and that is worth knowing before the screening call rather than after
• [362] Full Circle in Talar Osteochondral Defect Treatment: A 3-Decade Return to Microfracture — Giza E (sole author), Foot Ankle Int 2026 Mar;47(3):302-303, PMID 41736464, DOI 10.1177/10711007261418045. Eric Giza is the MASCOT principal investigator and Chief of Foot & Ankle at UC Davis — the surgeon this site already tells him to call. What makes this worth recording is its placement: it is the invited commentary on [266], Rikken/Kerkhoffs, immediately preceding it at 47(3):291-301 — the study finding that bone marrow stimulation for non-primary (revision) talar lesions yields median NRS-walking improvement of only 1/10 versus 3/10 for primary lesions (p=0.01). So the trial's PI wrote the commentary on the paper showing that the trial's comparator arm performs poorly in precisely this patient's category. Recorded with a hard limit, and the limit must travel with it: the body has not been read. Unpaywall reports is_oa: false, oa_status: closed, zero OA locations; SAGE is paywalled and a targeted search did not surface the text. Only the title, author, venue and pagination are verified, and the title is genuinely ambiguous — “full circle” could be endorsement of microfracture or lament that three decades produced nothing better. Do not resolve that ambiguity without the text. Its value is as a conversation opener with the one surgeon whose judgment most determines his trial access, not as evidence
• [363] UC Davis Department of Orthopaedic Surgery — Appointments and Referrals, read 2026-08-05. This one sentence unblocks an action item that has sat untouched since July: “Most UC Davis Health medical specialists require a referral from either a primary care physician or another specialist, either in the community or at UC Davis.” The August 4 finding that Dr. Salk cannot order a hip-to-ankle film was correct, but the site drew too broad a conclusion from it — a podiatrist cannot order the study and can still refer the patient to someone who can. Related UC Davis numbers verified the same day: Orthopaedics 916-734-5885 (fax 916-734-7904), Physician Referral & Transfer Center 916-734-8200, physician referral fax 916-703-6048, Consumer Resource Center 800-282-3284. Also re-verified unchanged: UC Davis still lists Anthem Blue Cross under “PPOs and standard insurance,” stamped “as of February 2026”
• [364] UC Davis Health — Insurance and Billing, read 2026-08-05. Determines whether the $33.57 applies at all. That rate sits under plan name “Ucd Hb Blue Cross Ppo” — hospital billing — and this page enumerates the hospital-based outpatient clinics: 4868 X St, 4860 Y St (ACC/Ellison), 2521 Stockton Blvd, 2279 45th St. The Davis (2660 W. Covell), Auburn, Midtown and Point West clinics are not hospital-based, so a film taken there would bill differently. Walk-in X-ray, Mon–Fri, from the radiology locations page: Main Hospital 4301 X St Suite 1776 (8–5, 916-734-0655), 48X Complex 4868 X St Suite 1C (8–5), ACC 4860 Y St Suite 0500, 8–5:30, check in Suite 1800 — the latest closing time of the three
• [365] CMS Medicare Physician & Other Practitioners — by Geography and Service, CY2024, HCPCS 77073. Queried 2026-08-05 to settle the last unknown in the alignment-film cost. The direct route failed and the failure is itself the finding: UC Davis's 113 MB machine-readable hospital file was downloaded and parsed in full — 34,790 items, 48,795 charge entries, billing class facility for 100% of them, zero professional lines — because physician groups are not covered by the hospital price-transparency rule, so a UC Davis professional file does not and will not exist. Medicare's claims data answers it instead: California, place of service F (hospital outpatient — professional component only), 347 providers, 4,858 services, average allowed $13.87; national F $13.11; California place of service O (freestanding, global) $41.59. This confirms the previously unverified $10–20 estimate and closes the item: all-in under $65. Also from the charge file: the CPT 77073 line is titled “HC BONE LENGTH SCANOGRAM,” and $33.57 is identical across Blue Cross PPO, HMO and Covered California
• [366] Sutter Health chargemaster files (Sacramento, Davis and Roseville), CPT 77073 “XR BONE LENGTH STUDY,” updated 2026-04-01, parsed 2026-08-05. $793 gross and $793 discounted cash — the same number, meaning no cash discount is offered at all. No Anthem commercial rate is published for the code at any of the three sites; Sutter Davis's only Anthem line is a Medicare Advantage rate of $135.68, which does not apply here. Recorded to answer a specific open question — whether any Sacramento-area facility sits between UC Davis's $35 and NorthBay's $2,057. Sutter does, at $793, and it is still roughly 24× the UC Davis negotiated rate. Also checked: Dignity/Mercy Greater Sacramento is unreached, not empty — all six of its published machine-readable-file links return HTTP 404; Kaiser publishes no non-member cash price; SimonMed has no Sacramento-area location
• [367] Vericel — Clinical Development page, read 2026-08-05. Carries a MASCOT-specific contact address that four previous sweeps missed: MACIANKLE@vcel.com, published under “Questions? Contact:” inside the MASCOT section. It is invisible to ordinary scraping — the page protects addresses with Cloudflare obfuscation, so a plain fetch returns no email at all; this was decoded from the page's data-cfemail attributes and confirmed. Same method also yields mail@vcel.com and grants@vcel.com. Corporate: Vericel, 25 Blue Sky Drive, Burlington MA 01803, 617-588-5555 — note the domain is vcel.com, not vericel.com. Already-known contacts re-confirmed current: clinicalhotline@vcel.com / 978-347-2876, and Leslie Mellor at UC Davis, 916-826-8135 / ljmellor@health.ucdavis.edu. Also checked and closed: the MyCartilageCare Assist copay program covers “the MACI implant only” for the FDA-approved indication, i.e. knee — no use for the ankle
• [368] Scripps Health & Anthem Negotiation — Scripps' own status page, stamped “Updated July 30, 2026,” re-verified 2026-08-05. “That extension is set to expire on September 30, 2026.” Not resolved and not extended — 56 days of runway from today. This matters because Dr. William Bugbee, author of the only published series of revision osteochondral allograft of the ankle, practises at Scripps (858-554-7993; Scripps Clinic foot & ankle 858-554-9300). Scripps still lists Anthem HMO/PPO as accepted and says patients “may continue to schedule appointments… as you normally would” for now. Anthem publishes no corresponding California page — every statement of this date traces to Scripps, so it is one-sided and worth confirming with Anthem directly before relying on it
• [369] Palomar Health Medical Group — Accepted Insurance, verified 2026-08-05: “Anthem Blue Cross HMO, PPO, EPO.” Recorded for Ariel A. Palanca, MD, 15611 Pomerado Rd 5th Floor, Poway CA 92064, 858-485-0050. Why she is worth a call: she is a co-author of “Fresh Osteochondral Allograft for Large Talar Osteochondral Lesions,” Foot Ankle Clin 2024 (PMID 38679444, with C.E. Gross) — the exact operation under discussion, not an adjacent one — and she is in San Diego County but not at Scripps, so a consult with her carries no exposure to the September 30 contract cliff [368]. Unverified: whether she is accepting new patients. Related and also new: Christopher E. Gross, MD (MUSC, Charleston, 843-876-0111), senior author of that paper and of “Hemitalus Allograft Transplantation for Osteochondral Lesions of the Talus” (2025, PMID 41362784), lists “Accepting New Patients: Yes” — out of state, Anthem California participation unverified
• [370] Eric Wan Tan, MD — Keck Medicine of USC, verified 2026-08-05. Profile states “Accepting New Patients” and lists Anthem Blue Cross Prudent Buyer, which is the actual name of California's Anthem PPO network — a detail worth carrying generally, since “are you contracted with Anthem Blue Cross Prudent Buyer PPO?” is unambiguous where “do you take Anthem?” is not. Phone 800-872-2273. Interests include cartilage preservation and restoration. Weighted honestly below Palanca [369]: no published talar structural-allograft work, so the on-point evidence is thinner. Also corrected this sweep: SCOI's redesigned site has no accepted-insurance page at all — billing now routes through UCLA Health — so the site's previous claim that Ferkel was the only surgeon with both “accepting new patients” and “Anthem” verified on one institutional page no longer holds. Ferkel himself remains active (818-901-6600, Van Nuys and Westlake), but his Anthem status is now unverified. Two further corrections: Duke's virtual second opinion is gone (the page 301-redirects, so the $800 Duke figure on this site is stale) and HSS's $800 second-opinion page now 404s
• [371] 45 CFR §149.610 and §149.620 — Good Faith Estimates and the patient-provider dispute resolution process, read verbatim from eCFR 2026-08-05. Nothing on this site has ever mentioned this, and he qualifies. §149.610(a)(2)(xiii)(B) defines an “uninsured (or self-pay) individual” to include a person with group coverage “who does not seek to have a claim for such item or service submitted to such plan or coverage.” Anthem excludes all hyaluronic acid class-wide under CG-DRUG-29, so no claim is submitted for Supartz — making him a self-pay individual for it as a matter of definition, and likewise for any cash-pay imaging. Entitlements: a written itemised estimate “not later than 3 business days after the date of the request,” or 1 business day when scheduled at least 3 business days ahead; dispute rights if the bill exceeds the estimate by $400 or more; a filing window “postmarked within 120 calendar days of receiving the initial bill” (§149.620(c)(1)); and refund of the administrative fee as a bill reduction if he prevails. CMS help line 1-800-985-3059
• [372] California SB 1120 (Chapter 879, chaptered 2024-09-28, effective 2025-01-01), read verbatim from leginfo 2026-08-05. Amends both Health & Safety Code §1367.01 and Insurance Code §10123.135, so it reaches Anthem under either regulator — the site previously cited §1367.01 only for its direct-phone-number provision and had nothing on this. Requires that no one may deny or modify a medical-necessity request except “a licensed physician or a licensed health care professional who is competent to evaluate the specific clinical issues involved”; and that any AI or algorithmic tool used in utilization review “does not base its determination solely on a group dataset” and “does not supplant health care provider decisionmaking.” Unusually well matched to this case: revision talar allograft has a world literature of one series of twenty patients, so a denial reasoned from population averages sits close to the statute's target. On any denial, ask in writing for the reviewer's name, licence type and specialty; whether an AI or algorithmic tool was used at any stage; and what patient-specific information that tool used. Scope limit, stated so it is not over-applied: this is a route for surgical and imaging denials. It will not move the HA exclusion, which is a benefit-design exclusion rather than a medical-necessity determination
• [373] CPT/HCPCS codes governing the procedures under consideration — gap identified 2026-08-05. This site carried 28446 (talar osteochondral autograft) and none of the three codes a revision decision would actually be adjudicated under: 27415 osteochondral allograft, 27416 osteochondral autograft, J7330 autologous chondrocyte implant (the MACI code). Payer medical policies are written per code, so “what is your medical policy for 27415?” retrieves a specific document where “cartilage surgery” retrieves a call-back. Pairs with the Good Faith Estimate route [371] and with PMID 36579033, “Variability in Private Payer Medical Policies for Osteochondral Allograft Transplantation Demonstrates the Absence of Standardization in Medical Criteria Between Payers” — authored by Bugbee, i.e. the surgeon most likely to perform this operation has published on payers denying it inconsistently. Also recorded out of window: Agili-C received a Category I CPT code effective 2027-01-01 (Smith+Nephew, 2025-10-09) — knee-only and it changes nothing today, but a Category I code is the reimbursement gate and is the kind of fact this file tracks
• [374] Gaul F, Tírico LEP, McCauley JC, Pulido PA, Bugbee WD — Osteochondral Allograft Transplantation for Osteochondral Lesions of the Talus: Midterm Follow-up, Foot Ankle Int 2019, PMID 30383977. Added 2026-08-06. The correct primary-OCA comparator, and the source of a correction. 19 patients / 20 ankles, mean graft 3.8 cm², 1998–2014: “Survivorship was 88.7% at 5 years and 81.3% at 10 years.” 5 of 20 ankles (25%) required further surgery; 3 were failures. Topic 30 had been quoting the 88.7% as a ten-year figure and deriving a 24-point revision penalty from it; the true gap against the revision series' 84%/65% is ~5 points at five years and ~16 at ten. Same authors, same institution, same era as [190] — the cleanest possible comparator, and it had never been cited here
• [375] Rucinski K, Cook JL, Schweser KM et al. — Short-Term Outcomes After Bipolar Osteochondral Allograft Transplantation (OCAT) in the Ankle, J Foot Ankle Surg 2024, PMID 37972816. Added 2026-08-06. Prospective registry, 14 patients — 12 primary and 2 revision OCAT, median follow-up 43 months (range 13–73), success in 13/14, OCA integration and joint space maintained in 12. Why it is here: it is the reason topic 30 no longer says n=20 is the entire world literature on revision ankle OCA. Two more revision cases exist, inside a bipolar registry. Bipolar (tibia + talus) is a different and larger operation than his, so this is a footnote to the count, not a comparator
• [376] MASCOT (NCT06915233) — the protocol design section, as distinct from the eligibility criteria. Pulled from the registry API 2026-08-06; record last updated 2026-07-23, status RECRUITING, masking NONE (open-label). Added 2026-08-06 because this site had read the criteria for months and never read the study design. Verbatim: “all participants will have an index ankle arthroscopy within 8 weeks to further assess clinical trial eligibility… participants will be further evaluated against entry criteria”; “All participants who meet the eligibility criteria… will have a cartilage biopsy taken prior to randomization… Participants randomized to Bone Marrow Stimulation will undergo the procedure during the Visit 2 ankle arthroscopy”; and “Participants assigned to the MACI treatment arm will return within 5 to 12 weeks… to undergo MACI implantation procedure via arthrotomy (Visit 3).” The word “biopsy” did not appear anywhere on this site before today
• [377] Vericel — FDA approval and commercial availability of MACI Arthro, 2024-08-26. Added 2026-08-06. The sBLA expanded the MACI label to arthroscopic delivery for knee defects up to 4 cm². Recorded because MASCOT specifies talar implantation via arthrotomy [376] even though the same manufacturer has an approved arthroscopic technique for the knee — which is a question worth putting to Vericel, not an inconsistency to assume. Also recorded so a later sweep does not re-chase it: an in-window news item (Long Island Press, 2026-08-04) describing an arthroscopic MACI case at Northwell Syosset is knee-only, never mentions the ankle, and misdates this approval to “late 2025”
• [378] NCT07555899 — Istituto Ortopedico Rizzoli, Bologna. Scaffold enriched with bone-marrow-derived cells at the subchondral level with retrograde drilling. RECRUITING, n=20, first posted = last updated 2026-04-29. Criteria pulled from the API and read in full 2026-08-06. No depth cap, no prior-surgery exclusion, no revision exclusion, no cyst exclusion — the complete exclusion list is age (18–55), active infection, HIV/HBV/HCV, pregnancy, autoimmune/rheumatologic disease, immune disorders, coronal malalignment, and “any other condition… that contraindicates surgical treatment.” Inclusion admits “chronic cystic subchondral lesions of the talus (Grade IIA according to the Giannini classification)” and “large chronic OCLs (Grade IIA)”. Contact Antonio Mazzotti MD PhD, antonio.mazzotti@ior.it, +39 349 879 8863. Italy, n=20 — a question to ask, not a plan
• [379] NCT06932380 — Vestre Viken Hospital Trust, Drammen, Norway. Episurf Episealer patient-specific metal talus implant, pilot, n=10. Status RECRUITING but last updated 2025-04-29, so the status is stale by more than a year. Added 2026-08-06 as the only trial found anywhere whose inclusion criterion affirmatively names prior surgery rather than barring it: “symptomatic osteochondral lesions of the ankle where conservative treatment or previous surgery has been unsatisfactory.” Not actionable — it excludes “patients unable to attend follow-ups due to distance” and “osteoarthritic changes on the tibial side”, and it is metal resurfacing (topic 19), not biological preservation. Recorded as a structural counterexample
• [380] Scripps–Anthem: the 2025 contract lapse actually happened. Added 2026-08-06. The contract “terminated effective January 1, 2025” and was not restored until May 6, 2025, leaving “over 125,000 Anthem policyholders unable to access in-network care”; the restoration was made retroactive to January 1, so claims were ultimately covered, but for four months patients had to find alternatives or invoke continuity of care. This is the missing half of the September 30, 2026 deadline — this site knew the extension existed but not that it followed a real lapse. These two parties have already demonstrated they will let it break. Corroborated at warnerpacific.com (“terminated effective January 1, 2025”); Becker's coverage 403s to automated fetches
• [381] CMS Medicare Coverage Database — route opened, and the structural negative it produces. Added 2026-08-06. The web app is gated behind an AMA CPT licence click and /v1/data/lcd returns 401, which is why three sweeps recorded this source as unreachable; api.coverage.cms.gov/v1/reports/* is open with no licence gate. Across 972 final LCDs and 345 NCDs (plus 95 proposed LCDs and 2,173 coverage articles): osteochondral 0, cartilage 0, chondrocyte 0, MACI 0, talus 0, talar 0, subchondral 0 — against live controls in the same payload of knee 8, allograft 10, hyaluron 2 (knee-OA policies only). Medicare has no coverage instrument of any kind for talar cartilage repair. Commercial payers anchor to Medicare; where Medicare is silent each payer writes its own rule, which is the mechanism behind Bugbee's own PMID 36579033 on payer-policy variability [373]
• [382] Kreulen C, Giza E, Walton J, Sullivan M — Seven-Year Follow-up of Matrix-Induced Autologous Implantation in Talus Articular Defects, Foot Ankle Spec 2018, PMID 28587484. Added 2026-08-06. The longest-follow-up MACI-in-the-talus series that exists, by the two UC Davis surgeons this site already tells him to call — and it had never been cited here. Prospective, 10 patients “who had failed previous arthroscopic treatment”, 9 followed to 7 years: AOFAS 61.8 → 78.3 (P = .05), with significant SF-36 gains in physical functioning, bodily pain and social functioning. Read the caveats with the headline: n=9, single arm, no control, Level IV — and the “revision” here is failed arthroscopic treatment (microfracture/debridement), not a failed structural allograft, so it is a nearer analogue than most of the literature but not his exact situation
• [383] Yang S, Hu F, Shao Q, Zhang Z — Autologous Osteoperiosteal Transplantation Versus Autologous Osteochondral Transplantation for Large Cystic Osteochondral Lesions of the Medial Talus: 2-Year Results From a Prospective Randomized Controlled Trial, Am J Sports Med 2025, PMID 40828751. Added 2026-08-06. A randomised trial, Level 2, n=70, restricted to large cystic lesions of the medial talus — the closest match to this lesion phenotype in the entire literature, and topic 26 did not hold it. Cystic diameter >8 mm; outcomes VAS, AOFAS, ankle activity score at 3/6/12/24 months plus MOCART and second-look ICRS. Honest limit: the PubMed abstract truncates before the outcome numbers, so the direction of the result is not stated here. Full text needed before any conclusion is drawn
• [384] Rikken QGH, Dahmen J, Reilingh ML, van Bergen CJA et al. — Outcomes of Bone Marrow Stimulation for Secondary Osteochondral Lesions of the Talus Equal Outcomes for Primary Lesions, Cartilage 2021, PMID 34167358. Added 2026-08-06 because it is the same group's opposite finding to [266], and this site held only one side of it. 12 secondary matched to 22 primary: NRS during activities 3 vs 2 (P = 0.5), return to sport 83% vs 90% (P = 0.6), no difference in CT fill. Why it does not rescue marrow stimulation for him: it is restricted to lesions <15 mm at 1-year follow-up. His is 15 × 10 mm with a cyst — at or past that ceiling — so the reassuring result does not reach him while [266]'s pessimistic one does. Recorded so that if a surgeon quotes this paper at him, the limitation is already in hand
• [385] Cavendish PA, Milliron EM, Peterson CJ et al. — What are the Chances of MACI Approval in the United States? A Deep Dive into the Insurance Authorization Data, Cartilage 2026, PMID 41802932. Added 2026-08-06. Vericel's own MyCartilageCare prior-authorisation dataset, 5,158 cases, 2021–22, ages 17–55: 87.7% approved on initial submission, 9.4% approved on appeal, 0.5% denied after appeal. The caveat is load-bearing and must travel with the numbers: this is a knee cohort, and MACI is FDA-approved for the knee only. Talar use is off-label, so these rates are a ceiling rather than his expectation. Still the only published payer-behaviour data on the product — and the 9.4%-on-appeal figure is the useful one, because it says appeals work roughly one time in ten
• [386] Bruns J et al. — Etiology, Classification, Diagnostics, and Conservative Management of Osteochondral Lesions of the Talus, Cartilage 2023, PMID 37082983. Added 2026-08-06 solely to define one term. Its Table 6 renders the Giannini staging, in which chronic Stage IIA is a lesion with a damaged (communicating) cartilage surface, ≥1.5 cm² and >5 mm deep. That matters because it is the entry criterion for [378]: a lesion of ~1.5 cm² with a 10 mm cyst reads as a direct match, which would make the very depth that disqualifies him from MASCOT the thing that qualifies him there. Stated with its limit: this is one source's table, the trial's own wording is internally ambiguous (it also says “with intact cartilage” of a different admitted category), and a second source consulted for cross-check described Hepple rather than Giannini. Treat as a question for the investigator, not a settled reading
• [387] Hollander JJ, Dahmen J, Stufkens SAS, Kerkhoffs GMMJ — Sustained Improvement in Pain with Talar OsteoPeriostic Grafting from the Iliac Crest (TOPIC) for Medial Osteochondral Lesions of the Talus: A Concise 5-Year Follow-up of a Previous Report, J Bone Joint Surg Am 2026, PMID 41364773. Added 2026-08-06. No abstract exists in PubMed — the record carries only the Level IV line — so no numbers are quoted from it here. Recorded because it is the formal journal-of-record five-year TOPIC report, alongside the 2024 Foot & Ankle Orthopaedics five-year paper already held as [145]
• [388] Usuelli FG, D'Ambrosi R — TOPIC at 5 Years: Promising Pain Relief, Unanswered Questions About the Relationship Between Structural Changes and Symptoms. Commentary on Hollander et al., J Bone Joint Surg Am 2026, PMID 41984065. Added 2026-08-06. The invited critical commentary on [387]; no abstract. The title is the finding available without the text: independent reviewers regard TOPIC's pain benefit as established and its structural claims as unsettled — the same distinction topic 27 already draws from other directions
• [389] Seo JH, Choi WS, Shin MY, Lee — Radiologic Progression of Talar Osteochondral Lesions With Subchondral Cyst: A Median 98-Month Observational Study, Foot Ankle Int 2026, PMID 42046994, DOI 10.1177/10711007261424901. Added 2026-08-06. The best long-term natural-history evidence that exists for the branch he is in right now, and this site was hosting a debate about it without holding it — [221] is the Dahmen/Kerkhoffs letter about this paper and [222] is the authors' response; the study itself was never here. 56 patients with cystic OLT managed non-operatively, median follow-up 98 months. Median annual cyst volume change 0.3 mm³/year; roughly three-quarters clustered at under 8 mm³/year of growth or actual shrinkage, while the upper quartile grew at ~137 mm³/year. Three predictors of progression on multivariable regression: larger initial cyst volume (OR 1.002, P = .03), bone marrow edema (OR 10.19, 95% CI 1.68–61.97, P = .012) and wall breakage (OR 16.94, 95% CI 2.73–105.35, P = .002). And two findings that cut against the intuition driving this whole file: “cyst size progression showed no correlation with clinical symptoms” and “none of the cases progressed to OA.” Retrospective observational cohort; abstract read in full, full text not retrieved
• [390] Cheng X, Zhao Y, Xu H et al. — Jumping Dot Sign: A New Radiological Sign Predicting Inferior Clinical Outcome and Higher Cyst Recurrence Following Bone Marrow Stimulation for Cystic Osteochondral Lesions of the Talus, Orthop J Sports Med 2025, PMID 40823644. Added 2026-08-06. A speckled high-signal pattern around the cyst on preoperative MRI, against a background of bone marrow edema, predicting cyst recurrence after marrow stimulation. Level 3 cohort. Directly relevant to the MASCOT comparator arm, and readable off imaging he already has. The limit that must travel with it, and which is easy to miss: the cohort was restricted to cystic OLTs under 150 mm², and his lesion is approximately 150 mm² — at or just past the ceiling of the population studied. So it is a question to raise, not a number to apply to him
• [391] DeFroda SF, Moore JM, Rucinski K, Cook JL et al. — High-Chondrocyte-Viability Osteochondral Allograft Transplantation in the Knee for Revision of Failed Cartilage Repair Procedures, J Knee Surg 2026, PMID 41022124. Added 2026-08-06. Prospective registry, 182 primary vs 70 revision OCA, mean follow-up 43 months. Functional graft survival 79.1% primary vs 71.4% revision — a much smaller gap than the ankle literature implies. The load-bearing detail is the subclassification by what failed first: revisions after a prior cell-matrix procedure had 100% graft survival, against 58.6% for revisions after a prior osteochondral procedure (P = .049). That second number is the closest published analogue anywhere to a second graft after a failed first graft. Satisfaction was still 75% and 84.1% would do it again. Knee, not ankle — read as mechanism, not as his prognosis
• [392] Meeker ZD, Knapik DM, Wagner KR, Cole BJ et al. — Comparison of Revision and Primary Osteochondral Allograft Transplantation at Midterm Follow-up, Am J Sports Med 2025, PMID 39972524. Added 2026-08-06 deliberately for balance, because it cuts against this site's pessimistic framing. 15 revision OCA of the femoral condyle matched 1:2 to 30 primary OCA, mean follow-up 9.3 years: no significant difference in survivorship (failure 13% revision vs 20% primary), though 53% required reoperation. Knee, Level 3, and n=15 is small enough that the absence of a difference may simply be low power — but a file that only records the discouraging studies is not an honest file
• [393] Kirilmaz A, Yaka H, Harmankaya M, Kekeç AF, Yıldırım A, Özer M — Is the Distal Tibial Slope Associated With Medial Osteochondral Lesions of the Talus? A Radiographic Case-Control Study. Research Square preprint, posted 2026-08-06, DOI 10.21203/rs.3.rs-9958316/v1, CC BY 4.0, no PMID. The only genuinely new item in this sweep's window. 76 medial-OLT patients vs 170 controls: distal tibial slope 5.10° vs 6.60° (P < .001); each 1° decrease OR 1.26; cut-off ≤4.6° OR 3.02; AUC 0.66. Every other radiographic angle was null (calcaneal inclination, lateral talocalcaneal, Böhler, Gissane, Meary), contradicting three prior studies from the same country. Read the disqualifiers before the result: not peer reviewed; the authors' own conclusion is “DTS should not be considered a diagnostic criterion”; AUC 0.66 is barely above chance; lesion size, depth and cyst status were not analysed at all; and the study's exclusion criteria — prior foot or ankle surgery — would have excluded Raymond himself. Its only real value here is that it names a sagittal-plane parameter measurable on a weight-bearing lateral radiograph he likely already has, and topic 28 is entirely coronal-plane. Hypothesis-generating, nothing more
• [394] Dr. Ariel A. Palanca — accepting new patients, resolved 2026-08-06. This had been an open question since August 5. Palomar Health Medical Group's own profile sets the flag in a JavaScript variable that no plain fetch renders: var acceptingNew = `yes`; — retrieved from the raw page source and confirmed. Orthopedics, Pomerado Outpatient Pavilion 5th Floor, 15611 Pomerado Road, Poway CA 92064, 858-485-0050. Insurance re-verified on the group's accepted-insurance page (modified 2026-04-28): “Anthem Blue Cross HMO, PPO, EPO.” She is now the cleanest match on the list: published on the exact operation (PMID 38679444), accepting patients, Anthem PPO, and not at Scripps. Method note: `palomarhealth.org` now 301-redirects to `palomarucsdhealth.org` and the profile lives on a third domain — any stored Palomar URL is stale
• [395] Dr. Timothy P. Charlton, MD — Cedars-Sinai, Los Angeles. Added 2026-08-06. The second California surgeon anywhere in this file with both “Accepting New Patients” and Anthem verified on one institutional page — the site's claim that Ferkel was the only one no longer holds. Read in a browser because the page is a JavaScript shell that returns 10 KB of nothing to curl or a plain fetch: profile states “Accepting New Patients” and “In-Person Visits,” with “Next New Patient Visit: Limited Availability.” Insurance list includes Anthem Blue Cross (the visible list does not spell out the PPO/Prudent Buyer variant — confirm by phone). Orthopaedics / Foot & Ankle; 444 S San Vicente Blvd, Mark Goodson Building, Los Angeles CA 90048; 310-423-9900; 31 years; Hospital for Special Surgery fellowship 2005; member AOFAS; reviewer for Foot & Ankle International and JBJS. Publication bar met, with an honest limit: he co-authored “Management of Osteochondral Lesions of the Talus,” Instr Course Lect 2017 (PMID 28594507) — with Eric Giza, the MASCOT principal investigator — but that is a review, not a talar structural-allograft operative series. Ask directly what he has actually done
• [396] Cedars-Sinai Virtual Second Opinion — the cheapest live remote second opinion found, and the only one that names a foot-and-ankle surgeon. Verified 2026-08-06, verbatim: “A Virtual Second Opinion from Cedars-Sinai costs $590 if you live in California or $790 if you live outside California”; “four to six business days after we complete the collection of your medical records”; and an optional live video session with the doctor to review the report — not a written-report-only product. The foot-and-ankle page names Dr. Charlton [395], so it routes to a surgeon who is also accepting in-person patients under Anthem if he wants to escalate. 310-423-4654. Routing caveat: entering via “Articular Cartilage Injuries” surfaces knee/sports surgeons — enter via the Foot & Ankle path and confirm the assignment before paying. Corrections to this site's stale second-opinion data: Duke's virtual second opinion is confirmed 404, and HSS's $800 page is 404 with the price now quoted at $1,400 — and no live HSS page supports the previously recorded claim that HSS excludes California
• [397] California Health & Safety Code §1373.65 — enrollee block transfer filings. Fetched and quoted 2026-08-06; not previously on this site, and it is the first two-sided read available on the Scripps deadline. (a) “At least 75 days before the termination date of its contract with a provider group or a general acute care hospital, the health care service plan shall submit an enrollee block transfer filing to the department”; (b) written notice to enrollees “at least 60 days before the termination date”; (c) — and this is the trap — “The health care service plan shall send enrollees of a preferred provider organization the written notice required by subdivision (b) only if the terminated provider is a general acute care hospital.” Two consequences. For a September 30 termination, Anthem's DMHC filing was due around July 17 and enrollee notices around August 1 — both already past, so whether a filing exists is knowable now. And as a PPO member he may receive no letter at all if what terminates is the Scripps physician group rather than a hospital — which is precisely where Bugbee sits. Ask DMHC directly: 1-888-466-2219
• [398] California DMHC Independent Medical Review determinations — the full decision database is machine-queryable, and this site had carried “look for prior talar cartilage IMR cases” as an open task. It is now done. Queried directly 2026-08-06 via data.chhs.ca.gov/api/3/action/datastore_search_sql against resource 3340c5d7-4054-4d03-90e0-5f44290ed095 — no browser, no login, full findings text. Hyaluronic acid: 458 decisions overturned against 132 upheld (I ran this count myself). Three ankle-specific HA overturns, all 2019 or later, and the older ankle cases all went the other way — the trend reverses around 2019 and has not gone back. MN21-36056 (2021, Overturned): “Current evidence suggests that viscosupplementation for treatment of ankle osteoarthritis is a safe and effective” method, for Synvisc-One HCPCS J7325 in the right ankle. MN20-33437 (2020, Overturned) turns on a fact pattern he shares: “the patient has a history of benefit from a prior viscosupplementation injection to the ankle.” MN19-31562 (2019, Overturned), same reasoning. Upheld cases are EI13-15767 (2013), MN11-12946 (2011), EI10-11704 (2010). The heavy caveat: these are medical-necessity denials that reached IMR. Anthem's HA exclusion is benefit design, and Ins. Code §10145.3(a)(4) / H&SC §1370.4 exclude contract exclusions from IMR — so this is not “file and win.” It is the evidence base for [399]
• [399] H&SC §1374.30 / Ins. Code §10169 — who decides whether something is an “exclusion” at all. Added 2026-08-06; neither was on this site. Two provisions matter. §1374.30(b) / §10169(b): where a denial rests on a finding that services “are not a covered benefit under the contract,” the decision “shall clearly specify the provision in the contract that excludes that coverage.” CG-DRUG-29 is an Anthem clinical policy bulletin, not a contract term — so the demand is that Anthem point at the section of his own Evidence of Coverage. Three outcomes, all useful: it cites a real EOC exclusion (now he knows), it cites only the policy bulletin (then it may not be a contract exclusion, and [398] becomes live), or it does not answer (a violation, itself complainable). §1374.30(d)(2)–(3): “The department shall be the final arbiter when there is a question as to whether an enrollee grievance is a disputed health care service or a coverage decision… If there appears to be any medical necessity issue, the grievance shall be resolved pursuant to an independent medical review.” The plan does not get to close the door by labelling. And §10169(l): “The insured shall pay no application or processing fees of any kind.” Filing costs nothing and forces the characterisation into the open
• [400] Bioventus Direct Purchase Program — the manufacturer sells Supartz FX direct for less than half what he paid. Verified 2026-08-06, verbatim: “SUPARTZ FX five-injection therapy: $85 (per injection)… GELSYN-3 three-injection therapy: $115 (per injection)… DUROLANE single-injection therapy: $450.” He paid $200 cash at Amazon Pharmacy for Supartz on 2026-05-07 — roughly 2.4× the manufacturer's own direct price. Bioventus customer service 1-800-836-4080. The honest catch, and it is the whole question: these products are FDA-indicated for the knee, and the programme is written around knee OA. His ankle use is off-label, which is legitimate prescribing but may or may not be something the programme will fill. One call settles it. Comparison point, also verified: Rx-Direct sells GenVisc 850 / TriVisc at “just $97 a syringe” — (866) 553-0112 — also knee-framed
• [401] Collignon F, Vaz G, Mainard D — “Traitement des lésions ostéochondrales du dôme du talus : état actuel, innovations thérapeutiques et perspectives d’avenir. Revue de la littérature” — Médecine et Chirurgie du Pied 41(2), published August 2026, DOI 10.1684/mcp.2026.0130. Added 2026-08-07 — the only genuinely in-window talus publication this sweep found anywhere (Crossref deposit 2026-08-06; not yet in PubMed). French-language narrative review from the Nancy group (CHRU Nancy / Université de Lorraine; corresponding author Didier Mainard). Abstract read in full, in French: debridement, drilling and microfracture are described as effective on small lesions but limited in their capacity to restore durable cartilage; osteochondral autografts and allografts, collagen matrices and particulated autologous cartilage as aiming to restore near-native architecture; and PRP, bone marrow concentrate and MSC adjuvants as widening the therapeutic field. A review, not new data — its framing matches the hierarchy this site already carries rather than changing it. Full text behind a JLE account wall; not read
• [402] Dahdouh R, Areslan K, Atallah K, Khalil LM, Badra M, Moucharafieh R — “Restoring the talar dome: A comprehensive review of treatment options for osteochondral lesions in adults” — Journal of Orthopaedic Surgery (Hong Kong), published May 2026, DOI 10.1177/10225536261476345, CC BY-NC. Added 2026-08-07 — surfaced by a Crossref deposit stamped 2026-08-07, so it is new to Crossref this week but three months old in print: a backfill catch of exactly the class the August 6 log warned about, recorded with honest dating rather than as news. Not yet indexed in PubMed — no PMID exists, which is why the DOI grep mattered for dedup. Abstract read in full: a narrative review across surgical modalities plus ESWT and injectable adjuncts, concluding that most approaches show satisfactory outcomes but “an ideal treatment algorithm is still elusive.” Full text not read: Sage now serves an unresolving Cloudflare interstitial to a real browser and 403s every fetch — the same blocking class as ScienceDirect. Re-pull when PubMed/PMC indexes it. Update 2026-08-08: PubMed indexed it within a day — PMID 42565217, already flagged MEDLINE — and it was the sole talus hit in the entire PubMed window, i.e. the “new” PubMed talus paper of the day was this known backfill, caught by the DOI/PMID grep. PMC still has no deposit (elink returns no PMC link), so the full text remains unread; the re-pull trigger is now a PMC deposit, not PubMed indexing
• [403] Vericel Q2 2026 earnings call (coverage dated 2026-07-31) — CEO Nick Colangelo, verbatim: “Vericel also began enrolling patients in its MACI ankle MASCOT study during the second quarter.” Added 2026-08-07. Until now this site's “MASCOT is actually enrolling” line rested on an inference — the 10-Q's attribution of rising research spend to “MACI MASCOT trial spend” [309]. This is a direct declarative company statement, and it carries a fact the registry does not: first patients entered in Q2 2026, i.e. by the end of June. The 8-K earnings release itself (SEC EDGAR, retrieved and grepped in full 2026-08-07) mentions the ankle exactly once, in forward-looking boilerplate (“timing and likelihood of the FDA’s potential approval of the use of MACI to treat cartilage defects in the ankle”) and gives no enrollment count; MASCOT appears zero times in the release. Method note: investors.vericel.com no longer resolves and vcel.com/news 403s a plain fetch — the SEC filing plus call coverage is the working route
• [404] Gelber PE, Ramírez-Bermejo E, Caviasso G, Juncosa-Chacón J, Fariñas O — “Bone Marrow Aspirate Concentrate Improves the Early Osseous Integration of Fresh Osteochondral Allografts in the Knee: A Randomized Controlled Trial” — Am J Sports Med 2026;54(7):1628–1635, Epub 2026-04-16, DOI 10.1177/03635465261437779, PMID 41992571, NCT04236492. Added 2026-08-08 — surfaced by an OrthoEvidence evidence-summary DOI deposited to Crossref 2026-08-07 (the in-window event; the paper itself is four months old and is recorded with honest dating, not as news). Barcelona group, single-center RCT, n=36, fresh osteochondral allograft transplantation of the knee with vs without autologous BMAC applied to the graft, serial CT at 3/6/12 months scored with ACTOCA. Osseous integration at the host–graft junction was superior in the BMAC group at 3 months (P < .05) with no difference at 6 or 12 months; graft signal density favoured BMAC at 3 months but favoured the non-BMAC group at 12 months; and no differences in any patient-reported outcome at 2 years. Abstract read in full. Level 1, knee not talus, primary transplants not revisions — mechanism evidence for the augmentation question, not a promise
• [405] Yanke AB, Dandu N, Bodendorfer BM, Trasolini NA, Hevesi M, Elias TJ, Haneberg E, Darwish RY, Zavras A, Forsythe B, Cole BJ — “Bone Marrow Aspirate Concentrate May Decrease Reoperation in Osteochondral Allograft Transplantation: A Prospective, Randomized, Double-Blind Investigation” — Arthroscopy 2025;41(11):4664–4673, DOI 10.1016/j.arthro.2025.05.024, PMID 40482979. Added 2026-08-08, found by following [404]'s citation trail — nine months old, new to this site. Rush group, n=36, knee OCA randomized to iliac-crest BMAC vs sham incision, patients blinded, 6-month CT scored with the same semiquantitative system as [404]. The cyst findings cut both ways and are quoted exactly: BMAC grafts “were more likely to have small cystic changes (P = .01), with an associated trend toward reduction in large cyst formation (P = .06), but equal osseous integration.” The headline: reoperation for graft debridement or revision 5.3% with BMAC vs 35.3% without (P = .02), with no PROM differences at any timepoint and a non-significant trend toward more MCID achievement (88% vs 55%, P = .076). Abstract read in full. Funding disclosed: JRF Ortho supported the study — a graft vendor, noted because it is the kind of detail this list exists to carry
• [406] Zhang M, Ni S, Ng L, et al. — “Exploring the effectiveness and safety of stem cell therapy for repair of cartilage defects: a meta-analysis of randomized controlled trials” — Frontiers in Cell and Developmental Biology 14, published 2026-08-07, DOI 10.3389/fcell.2026.1880031. Added 2026-08-08 — genuinely in-window, open access, read from the publisher page. 24 RCTs, 1,389 patients — and every included trial is knee (inclusion criteria restrict to “cartilage defects of the knee joint”), so it changes nothing about the ankle evidence count on topic 10, which remains eleven non-randomised studies. Pooled: pain SMD −1.31 (95% CI −1.82 to −0.81, I² = 91.3%), WOMAC −0.78, cartilage volume +0.91; adverse events no different from control (OR 1.58, 95% CI 0.72–3.47), mild and transient. The two subgroup findings worth carrying: autologous cells outperformed allogeneic (SMD −1.88 vs −0.80) and bone-marrow-derived outperformed adipose-derived on cartilage volume — directionally consistent with [404]/[405] using autologous marrow, and with the site's standing caution that the standalone-injection evidence in the ankle is still two studies and a case report
• [407] Zhou Q, Shen Q, Gao Z, Shi W, Guo Q — “HRX-215 attenuates cartilage fibrosis in osteoarthritis progression and microfracture repair by targeting MKK4” — Biochemical Pharmacology, Epub 2026-08-08 ahead of print, DOI 10.1016/j.bcp.2026.118336, PII S0006295226006751, PMID 42570848. Added 2026-08-09 — genuinely in-window (Crossref deposit and PubMed epub both 2026-08-08); abstract read in full, full text paywalled. Peking University Third Hospital sports-medicine group. Preclinical, rats and human chondrocytes — no human trial. The claim: cartilage fibrosis is “the direct cause of repair failure due to fibrocartilage formation after microfracture surgery,” MKK4 is upregulated in OA cartilage (GEO datasets plus their own clinical samples), and the oral MKK4 inhibitor HRX-215 delayed cartilage degeneration and fibrosis in both a rat ACLT osteoarthritis model and a rat microfracture model, while promoting chondrocyte proliferation and slowing oxidative-stress-driven matrix degradation in human chondrocytes. What separates this from the usual preclinical entry: HRX-215 is already a clinical-stage human drug — HepaRegeniX's liver-regeneration candidate, with a completed first-in-human safety trial published in Cell (March 2024, well tolerated at all doses) and a Phase Ib in liver-resection patients completed in early 2026. A molecule with human safety data being aimed at the fibrocartilage problem is a shorter repurposing distance than the field's usual mouse-only candidates — but the cartilage work is rodent-only, no joint indication is in trials, and the authors declare no competing interests
• [408] — “Navigating Conservative Strategies for Ankle Osteoarthritis Treatment: Understanding Footwear Preference — Rocker Bottom Shoes and Ankle Foot Orthotics” — Journal of Prosthetics and Orthotics, first published 2026-07-01, DOI 10.1097/JPO.0000000000000608, PMID 42569411. Added 2026-08-09 — five weeks old, surfaced by in-window PubMed indexing (crdt 2026-08-08); recorded with honest dating. Pilot cross-over study, n=10, doctor-diagnosed ankle OA, telehealth design: each participant wore control shoes, rocker-bottom shoes, and an AFO for 3 weeks each, with PROMIS/FAAM and pain ratings after each block. No significant differences in pain or function across the three conditions — but preference split cleanly by age: participants aged 56–63 preferred the AFO for pain relief and mobility, those 66–75 preferred rocker-bottom shoes for comfort, and the AFO-preferring group showed significant reductions in maximum pain versus the rocker group. Tiny, unblinded-by-nature, and preference-confounded — carried because the site's bracing page recommends exactly these two device classes and this is the first study to put them head-to-head in ankle OA, however small
• [409] Tabbaa SM, McCauley JC, Crawford DC, Bugbee WD — “Association of Donor Characteristics and Graft Storage Time with Survivorship of Osteochondral Allograft Transplantation in the Knee” — Orthop J Sports Med 2026, DOI 10.1177/23259671261457786, Crossref-created 2026-08-11. Added 2026-08-11, in-window. Senior author is Dr. William Bugbee at Scripps — the same fresh-allograft program on this site's action list, publishing from its own graft registry. 220 patients / 236 knees, primary fresh OCA, minimum 2-year follow-up (mean 8.2 years), degenerative indications excluded. Level 3. Findings: grafts from donors older than 20 failed at 11.7% vs 3.7% for donors ≤20 (P=.039; 10-year survivorship 89.3% vs 100%; hazard 6.96×). Early-release grafts (1–14 days storage) failed at 22.7% vs 6.0% for late-release (15–28 days) (P=.002; 10-year survivorship 85.6% vs 96.1%; hazard 6.90×) — the opposite of the fresher-is-better intuition. Donor BMI and donor-recipient sex matching made no difference, and IKDC/satisfaction did not differ across groups. Honest limits: knee, not talus; observational, so the early-release signal is association (early-released grafts may differ in ways the registry does not capture), and the authors frame it as evidence that longer storage within the 28-day window is not harmful rather than protective. Update 2026-08-14: PubMed indexed it — PMID 42591544, caught when it surfaced as an in-window PubMed candidate and the DOI grep matched this entry; [411] still awaits its PMID
• [410] Linstrom NW, Bugbee WD, Wang T — “Conditional Survivorship of Osteochondral Allograft Transplantation in the Knee” — Orthop J Sports Med 2026, DOI 10.1177/23259671261468538, Crossref-created 2026-08-10. Added 2026-08-11, in-window; companion to [409] from the same Scripps program. Update 2026-08-13: PubMed indexed it — PMID 42582660, caught when it resurfaced as an in-window PubMed candidate and the DOI grep matched this entry; [409] and [411] still await theirs. 288 knees / 267 patients, single surgeon (Bugbee), 1997–2015, minimum 10-year follow-up, median age 33. Level 4. Overall survivorship 78% at 10 years; graft failure in 22% at a median of 2.7 years. The useful shape: annual failure ran 4.9% per year in the first 3 postoperative years, then dropped to 1.5% per year from years 3–10 — a graft that clears its first three years has earned a much lower ongoing risk. Knee data, but it is the survivorship curve of the exact program and surgeon this site's allograft thread points at, and the front-loaded-failure shape matches how this ankle's own 2012 graft behaved (survived long past the high-risk window before late decline)
• [411] Wang J, Li G, Zhang J, Fu S, Wang C, Wu C, Zhang S, Ma X, Shi Z — “Autologous costochondral transplantation in the treatment of Hepple V osteochondral lesions of talus: a retrospective analysis” — J Orthop Traumatol 2026, DOI 10.1186/s10195-026-00961-3, published 2026-08-12 (unedited early-access version), open access. Added 2026-08-12, in-window; abstract read in full from the publisher page. Shanghai Sixth People’s foot-and-ankle group (Xin Ma, Zhongmin Shi). The first head-to-head comparison of autologous costochondral transplantation (ACT) against osteoperiosteal transplantation (OPT) in Hepple V talar lesions — 53 patients / 53 ankles (27 ACT, 26 OPT), operated February 2020 – February 2022, Level IV retrospective cohort. Outcomes FAAM-ADL, FAAM-Sports, EQ VAS and MOCART 2.0. Both groups improved significantly; postoperative scores at every follow-up point favoured ACT; and ACT’s MOCART 2.0 kept improving between 12 months and final follow-up while OPT’s plateaued. Complications: hardware removal in 3 ACT (11.1%) vs 2 OPT (7.7%), one poor wound healing; no non-union, delayed union or neurovascular injury in either arm. Authors’ conclusion verbatim in direction: ACT showed superior functional outcomes, higher satisfaction, fewer complications and quicker early mobilization. Honest limits: retrospective, not randomized; single center; outcome numbers not extracted here because the early-access PDF was not parsed — directions and P-thresholds only; and the 27-ankle ACT arm from this hospital very likely overlaps the 27-patient rib-cartilage cohort already carried as [176], so this is the same program comparing its technique against an alternative, not an independent replication
• [412] Parente A, Marotta N, Demeco A, Madia D, Longo UG, Ammendolia A, de Sire A — “Effects of a multimodal technology-assisted rehabilitation program in a patient undergoing total ankle and total talus replacement: a paradigmatic case report” — J Back Musculoskelet Rehabil, Epub 2026-08-11 ahead of print, DOI 10.1177/10538127261476802, PMID 42578892. Added 2026-08-12, in-window. n = 1 — a 59-year-old man with talar avascular necrosis and advanced ankle OA after fracture-dislocation, treated with combined total ankle + total talus replacement (TATTR, January 2025), then a structured 5-month rehabilitation: joint mobility, progressive strengthening, proprioceptive training (Pro-Kin), antigravity-treadmill gait retraining and visual-feedback gait optimization. Berg Balance 30 → 56, Tinetti 9 → 29, EQ-5D index 0.169 → 1.0, eyes-closed sway ellipse 318 → 77 mm² at 5 months. Carried for one narrow reason: the end-stage page holds four FDA adverse-event reports and survivorship caveats for TATTR but nothing on what structured recovery after it looks like — this is the first published rehab protocol with serial quantified outcomes. A single case report proves nothing about the operation; it documents that a monitored recovery to independent function within 5 months is at least possible in a 59-year-old, and names the rehab components used
• [413] NCT06897098 — “Autologous Cartilage Implantation: Safety Study for Focal Chondral Lesions in the Knee and the Ankle” (Cartibeads), Geneva University Hospitals + Hirslanden La Colline + EOC Lugano — status changed to COMPLETED in the 2026-08-11 registry update (actual completion 2025-04-02, first posted 2025-03-26). Added 2026-08-12, in-window registry event. Phase 1 single-arm safety trial, n = 11 actual, adults with ICRS grade 3–4 focal lesions 1.5–10 cm², 12-month follow-up. The technology is the reason to carry it: Cartibeads are 1–2 mm mini-grafts of genuinely hyaline cartilage engineered from the patient’s own expanded chondrocytes via a patented dedifferentiation-reversal step — aimed at the exact fibrocartilage problem that limits microfracture and first-generation ACI — and the protocol explicitly includes the ankle, which almost no cell-therapy trial does. Registry record only; no results posted yet and no publication found. Swiss trial, completed, so not an enrollment option — the action is watching for the results publication, which the completed status now makes due
• [414] Backus JD, Schon LC, Ledoux WR, Coleman MC, Collins KH, Ellis SJ, Lenz A, de Cesar Netto C, Demetracopoulos CA, Lane NE, Wilken J, Amendola A, et al. — “Advancing Prevention and Treatment of Ankle Osteoarthritis: A Translational Clinical Roadmap from the 2026 AOFAS/Arthritis Foundation Ankle Arthritis Think Tank” — Foot & Ankle Orthopaedics, DOI 10.1177/24730114261464607, Crossref-created 2026-08-13T08:07Z. Added 2026-08-13, in-window — created the morning of the sweep. The Arthritis Foundation and AOFAS convened an Ankle Arthritis Think Tank in Napa on January 22, 2026, and this is its published synthesis: four structured sessions — (1) biologic and biomechanical pathogenesis, (2) diagnostic and management challenges, (3) therapeutic strategies, (4) research methodology — closing with a moderated discussion to identify “actionable and fundable research pathways” for the next decade. The framing is the field indicting itself, verbatim from the abstract: ankle OA “is predominantly post-traumatic in origin,” “differs in important ways biologically, mechanically, and clinically from hip and knee OA,” and its treatment strategies “remain largely reactive and centered on end-stage reconstruction” — convened explicitly “to solve patient frustration of limited treatment options and relatively poor outcomes.” The author list is a who’s-who of the programs this site already tracks: Schon, Ledoux, Ellis and Demetracopoulos (HSS), de Cesar Netto, Lane, Amendola (Duke). Honest limits: a consensus-meeting synthesis, not data — it produces priorities, not treatments; and only the abstract has been read — Sage serves an unresolving bot-challenge to a live browser and 403s every fetch (same blocking class as [402]); no PMID yet; the PMC deposit, when it appears, is the full-text re-pull trigger
• [415] Wang S, Xue Y, Zhuang J, Xu N, Zhang Z, Tan G, Jiang H, Wu R, Shi D — “Betaine Downregulates RARRES1 to Alleviate Cartilage Fibrosis and Promote Hyaline Cartilage Repair” — Int J Mol Sci 2026;27(15):6684, published 2026-07-27, DOI 10.3390/ijms27156684, PMID 42589340, open access. Added 2026-08-13 — two weeks old, surfaced by in-window PubMed indexing (crdt 2026-08-12/13); recorded with honest dating. Nanjing Drum Tower Hospital bone-and-joint laboratory. Preclinical. Bulk and single-cell RNA-seq identified RARRES1 as a biomarker of cartilage fibrosis, confirmed upregulated in damaged human OA cartilage; in a CTGF-induced chondrocyte-fibrosis model with siRNA knockdown, betaine downregulated RARRES1, upregulated RGS2, cleared reactive oxygen species, alleviated fibrotic change and promoted hyaline repair in vitro and in vivo. Carried because it lands on the same fibrocartilage problem as [407] and [173] from a different angle — and because betaine is an over-the-counter supplement (trimethylglycine), which puts it adjacent to the nutrition page. The limits do the real work here: cell and animal models only, no human joint trial, no dosing data, no reason to buy anything — a supplement having a plausible mechanism in a dish is the beginning of a research program, not a treatment
• [416] Koenig FRM, Janacova V, Schreiner M, Stuempflen M, Juras V, Szomolanyi P, Varga R, Wollner G, Patsch JM, Filardo G, Guermazi A, Trattnig S — “Routine MRI Signal Intensity as a Surrogate of Subchondral Bone Healing: Validation Against Micro-CT and Histology in an Ovine Model” — Diagnostics 2026;16(15):2426, published 2026-07-31, DOI 10.3390/diagnostics16152426, PMID 42587663, open access. Added 2026-08-13 — two weeks old, surfaced by in-window PubMed indexing; recorded with honest dating. Vienna High-Field MR Center — senior author Trattnig is the originator of the MOCART scoring system this site’s imaging thread leans on, with Filardo and Guermazi as co-authors. 28 sheep, bilateral trochlear defects (tri-layered resorbable scaffold vs empty control), cohorts at 30/180/365 days; blinded radiologist Likert reads on routine T1-SE and PD-FSE sequences correlated with micro-CT new-bone volume and with histology; PD-FSE contrast-to-noise ratio tracked bone regeneration inversely (P < .001, lower CNR = more new bone); T1-SE CNR did not track mineralization and should not be used alone. Inter-reader agreement excellent (ICC 0.947–0.973). Carried for topic 27’s exact question — what a bright or dark patch under a repaired defect on an ordinary follow-up MRI actually means: this is the first validation of those routine signals against ground truth. Honest limits: sheep knees, not human tali; scaffold repair, not allograft; it supports interpretation of follow-up scans, not treatment decisions
• [417] FDA MAUDE, two further adverse-event reports for 4WEB custom total-talus implants — MDR keys 25828483 and 25828494, both received 2026-07-15, both from 4WEB’s routine annual patient-specific-implant survey. Added 2026-08-13, surfaced by the first MAUDE refresh since July 28 (dataset last_updated 2026-08-05; date_received frontier advanced 2026-06-30 → 2026-07-31, closing the 39-day blind spot the August 5–8 logs measured). Report one (25828483): total-talus subsidence after a 2024 implant — a 2025 revision injected synthetic bone substitute to halt it, then a further 2025 revision explanted the total talus/total ankle INBONE stem entirely and converted to tibiotalocalcaneal fusion with another manufacturer’s spacer. Report two (25828494): after total talus with subtalar fusion in a patient with pre-existing ankle and subtalar arthritis and talar AVN, the fusion was “felt to be unstable and a persistent source of pain and disability” — and the patient elected below-knee amputation, the first amputation outcome in this device class’s reports. Counts, updated: product code QNN now has 20 reports all-time (18 at the August 5 backfill), six received in 2026, five of them 4WEB. The standing limits travel with this entry: no denominators, counts are not rates, no manufacturer defect findings, and survey-solicited reports skew toward surgeons who answer surveys. What the pair adds is not a rate but a rung: the end-stage page’s escalation ladder — each revision spending another joint — now has documented endpoints at fusion-conversion and at amputation
• [418] NCT06897111 — “Implantation of Allogenic Cartilage Mini-grafts: First-In-Human Study for Treating Chondral Lesions of the Knee” — Vanarix SA, phase 1/2, n = 10 actual, ACTIVE_NOT_RECRUITING, first posted 2025-03-26, record untouched since. Added 2026-08-13 — out-of-window context, recorded with honest dating: surfaced by the Cartibeads results-watch search, not by a registry event. The relevance is the sponsor and the cell source: Vanarix SA is the lead sponsor of both this trial and the completed autologous Cartibeads trial [413], and this one implants the same engineered hyaline mini-grafts made from donor cells — the off-the-shelf version. Knee only, 6-month follow-up, no results posted. Why it earns a line on a talus site: the two-stage harvest-then-implant problem is a real cost of every autologous cell therapy (MACI included, per the MASCOT design notes) — if the allogeneic variant proves safe, that cost disappears; and a completed autologous safety trial plus an active allogeneic one means the Cartibeads results publication [413] is worth watching for both
• [419] Han X, Long Y, He W — “Molecular-biomechanical phenotyping of ankle osteoarthritis: from synovial biomarkers to weight-bearing digital signatures” — Frontiers in Medicine, published 2026-08-13, DOI 10.3389/fmed.2026.1931266, open access. Added 2026-08-14, in-window (Crossref-created 2026-08-13T14:00Z, one day before the sweep). A Mini Review, not data — but it is the first published attempt to do for ankle OA what the [414] roadmap’s diagnostics session asked for: an ankle-specific precision framework. Argues the case from three directions this site already carries piecemeal — ankle OA is enriched for post-traumatic mechanisms, ankle cartilage biology differs from knee (catabolic susceptibility, matrix synthesis, transport, injury response), and the ankle is unusually measurable (weight-bearing CT, automated 3D alignment metrics, distance maps, gait analysis, plantar pressure, activity monitoring). Proposes four provisional baseline research phenotypes: inflammatory-dominant, malalignment-dominant, post-traumatic/instability-dominant, and end-stage structural collapse — with post-surgical recovery treated as a longitudinal trajectory rather than a fifth phenotype. The authors grade their own evidence: mature for ankle-knee cartilage differences, preliminary for synovial biomarkers and digital signatures. Honest limits: provisional research phenotypes with no prospective validation, no treatment implications yet, and a framework paper cannot change a 2026 care decision — carried because it operationalizes the roadmap’s diagnostic session and names the exact instruments (WBCT, gait, alignment metrics) already argued for on topic 28
• [420] Tsai MC, Lee YS, Lee TC, Li YC, Yang KC, Wang CC — “Distal Tibial Oblique Osteotomy Combined with Strut Bone Allografting for the Treatment of Ankle Osteoarthritis with Varus Deformity: A Case Series” — Journal of Clinical Medicine 2026;15(16):6298, published 2026-08-14, DOI 10.3390/jcm15166298, open access. Added 2026-08-14, in-window — Crossref-created the morning of the sweep (2026-08-14T09:04Z). Retrospective case series, Taiwan: 20 ankles with Takakura stage IIIa (13) or IIIb (7) varus ankle OA — advanced disease, tilt inside the mortise — treated 2012–2024 with distal tibial oblique osteotomy plus a structural strut allograft in the osteotomy gap. Results: MOXFQ 57.7 → 10.6, AOFAS 63.8 → 85.5, VAS 4.3 → 1.0 (all P < .001); radiographic union in all 20 within 3 months; TAS, TLS, MMA and TTS all corrected significantly. The honest detail that keeps this useful: talar tilt angle did not significantly change (P = .336) — the osteotomy reorients the tibial plafond around the talus rather than de-tilting the talus itself, and the good clinical scores arrived anyway. Why it earns a line here: Takakura III has historically been the boundary where joint-preserving realignment gives way to fusion or replacement, and this series argues the boundary is softer than the staging implies. Honest limits: Level IV, 20 patients, no comparison arm, follow-up length not stated in the abstract, and a varus-deformity operation says nothing directly about a post-allograft talar lesion — it goes to the alignment thread (topic 28), not the revision decision
• [421] Hu Q, Qi B, Dong Y, Pan Y, Liu Y, Chen Z, Fang J, Liang Y, Zhang P — “Skeletal interoception regulates joint homeostasis and PGE2-induced pain: implication of disease-modifying treatment” — Bone Research 2026;14(1):84, published 2026-08-13, DOI 10.1038/s41413-026-00561-1, PMID 42595748, open access. Added 2026-08-14, in-window. Zhejiang Chinese Medical University (acupuncture-research department — declared plainly, because it shapes the therapeutic sections). A review, not data — carried for one narrow mechanistic reason: it is the mirror image of the 15-PGDH thread. The site’s most-watched preclinical program [173] proposes to regenerate cartilage by raising PGE2 (inhibiting the enzyme that degrades it); this review assembles the skeletal-interoception literature in which PGE2 signaling through sensory nerves is a driver of osteoarthritis pain — naming ankle OA specifically, with ankle pain prevalence of 9–15% in adults — and reads NSAIDs, surgery and acupuncture through that lens. The tension is not a contradiction (local regeneration signaling and sensory-nerve pain signaling are different compartments and timescales) but it is real, and any future 15-PGDH joint trial will have to walk it: the same molecule the regeneration program wants more of is the one the pain literature wants damped. Honest limits: narrative review; the TCM/acupuncture treatment sections are the authors’ own program and are not evidence for any intervention; nothing here changes a care decision — it annotates the 15-PGDH entry with the other half of the PGE2 story
• [422] Rubin J, Tham A, Allen M, Butler JJ, Montgomery SR Jr, Mercer NP, Lezak BA, Zaifman J, Kennedy JG — “Hyaluronic Acid in the Management of Foot and Ankle Pathologies” — Foot & Ankle Specialist, Epub 2026-08-14 ahead of print, DOI 10.1177/19386400261477453, PMID 42598895. Added 2026-08-15, in-window — Crossref-created 2026-08-14T10:59Z, PubMed-indexed the same day. NYU Langone foot-and-ankle division; senior author John G. Kennedy, among the most-published surgeons in talar cartilage repair — the first time this site carries a paper from that group on the HA question. A scoping review, Level V — the weakest evidence class on topic 29, and it is carried anyway for one reason: it is the first HA synthesis published after the July 2026 AAOS guideline, and it separates the evidence by indication instead of treating “the ankle” as one thing. Findings, in the authors’ own ordering: the most consistent support is for soft-tissue conditions (Achilles tendinopathy, plantar fasciitis, acute lateral ankle injury); for osteochondral lesions of the talus and selected OA, HA “may be used as an adjunct,” with outcomes “heterogeneous across studies”; overall the evidence “remains limited by heterogeneous study designs, inconsistent treatment protocols, and short-term follow-up,” against a favorable safety profile. This does not overturn the AAOS recommendation and does not attempt to: AAOS graded HA monotherapy for symptomatic ankle OA, this review surveys a wider indication set and lands on “adjunct, selected cases.” Both can hold simultaneously. Honest limits: scoping review, no new patients, no pooled effect estimate, no ankle-specific dosing protocol, and nothing here is data on a post-allograft Hepple V cystic lesion — the exact gap topic 29 has flagged since it was written. Practical value is one framing change for the August 18 appointment, four days after publication and two days after the HA washout clears: the question to put to the surgeon is not HA-versus-nothing but HA as an adjunct with a failure threshold set in advance